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 Mycobacterium tuberculosis (M. tb) is the causative agent of tuberculosis (TB), a severe 
lung infection that causes 1.4 million deaths per year. During infection, M. tb is able to subvert 
host immune responses and survive within the macrophage by using its type-7 early secreted 
antigenic target (ESAT-6) system 1 (ESX-1) to secrete virulence protein effectors including EspB. 
A previously published study showed that EspB has a virulence function distinct from other ESX-
1 secreted proteins that may be dependent on phospholipid binding. The objective of this thesis 
project is to determine the molecular basis of EspB-phospholipid interactions and whether 
oligomerization of EspB is critical for its interaction with phospholipids and consequently 
important for its virulence function. 
 Amino acids in EspB predicted to be critical for phospholipid binding (R17, H223, F159, 
and I246) or oligomerization (W176, K259, and K267) were replaced. Recombinant EspB variants 
(EspBR17A/H223A, EspBF159R/I246R, EspBW176R, and EspBK259A/K267A) were produced in Escherichia 
coli (E. coli) and were assessed for oligomerization and phospholipid binding. 
 Two EspB variants, EspBR17A/H223A and EspBF159R/I246R were shown to form hyper-
oligomers in native polyacrylamide gel electrophoresis (native-PAGE), dynamic light scattering, 
and transmission electron microscopy analyses. EspBW176R and EspBK259A/K267A did not appear to 
have significant differences in oligomerization compared to EspBWT. Replacement of the residues 
R17 and H223 in EspBR17A/H223A abolished its phospholipid binding ability, whereas the 
replacement of residues in F159 and I246 in EspBF159R/I246R appeared to enhance phospholipid 
binding. EspBW176R was able to bind phospholipids similarly to EspBWT and EspBK259A/K267A was 
shown to have reduced binding. Addition of purified EspBR17A/H223A to the M. tb 5’Tn::pe35 strain 
was able to enhance the induction of THP-1 macrophage cytotoxicity similarly to EspBWT. 
 The residues R17 and H223 appear to be important for phospholipid binding. However, 
mutation in predicted critical oligomeric sites of EspB did not have a significant impact on its 
phospholipid binding ability. Although phospholipid binding ability was predicted to affect the 
virulence function of EspB, purified EspBR17A/H223A was still able to induce cytotoxicity in THP-1 
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1.1. Mycobacterium tuberculosis 
 Mycobacterium tuberculosis (M. tb) is the causative agent of tuberculosis (TB) in humans, 
which is one of the major causes of death due to a single infectious disease agent in the world. In 
addition to M. tb, TB can be caused by other members of the Mycobacterium tuberculosis complex 
(MTBC) such as Mycobacterium bovis (M. bovis) and Mycobacterium africanum (M. africanum) 
(Forrellad et al., 2013; de Jong et al., 2010). TB primarily affects the lungs but can spread to any 
other organ in the body (Pai et al., 2016). Each year, approximately 10 million people fall ill with 
TB and 1.5 million people die due to this disease (Geneva: World Health Organization, 2020). 
 Infection with M. tb can lead to several outcomes: clearance of the infection, latent disease, 
or active disease (Lin and Flynn, 2018) (Figure 1.1). Some infected individuals may be able to 
Figure 1.1. Possible outcomes of TB disease in humans. In immunocompetent individuals, there 
is a chance of bacterial clearance. However, most individuals develop latent disease, which is an 
asymptomatic, non-transmissible state. Individuals who are immuno-deficient may develop active 
disease, which is symptomatic and transmissible. 
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clear the bacteria and do not progress to active TB (Lin and Flynn, 2018). In most cases, the 
individual can develop latent TB, which is an asymptomatic, non-transmissible state of infection 
(Delogu and Fadda, 2009; Ernst, 2018; Flynn and Chan, 2001). Often times, latent TB can go 
unnoticed for many years (Lin and Flynn, 2018; Silva Miranda et al., 2012). In this case, M. tb is 
able to survive within the host and evade the immune response (Lin and Flynn, 2018; Silva 
Miranda et al., 2012). Individuals with latent TB become a reservoir for the bacteria with a 10% 
chance of reactivation into active disease (Silva Miranda et al., 2012). Reactivation is especially 
likely in immunocompromised individuals such as human immunodeficiency virus (HIV)-positive 
patients, older individuals, and individuals with other underlying medical conditions including 
malnutrition and diabetes (Silva Miranda et al., 2012). In active TB, clinical symptoms are present 
and the infection is transmissible to other individuals. Some of the symptoms of active TB include 
fever, weight loss, fatigue, persistent cough, and hemoptysis (Pai et al., 2016). 
 Although there is an established treatment for TB, the drug treatment has remained 
unchanged for the last 50 years (Lin and Flynn, 2018). In addition, treatment of TB involves a 4 – 
6 month regimen of 4 antibiotics: isoniazid, rifampin, pyrazinamide and ethambutol (Pai et al., 
2016). Even with the established treatment of TB, there is a rising problem with drug-resistant M. 
tb. Since this treatment is accompanied with severe side effects, this could lead to poor patient 
compliance (Iacobino et al., 2020). Furthermore, poor drug regimen selection and sometimes the 
lack of availability of drugs especially in smaller, more isolated countries can lead to the inability 
of the patient to finish the treatment, contributing to the rise in drug resistant M. tb (Iacobino et al., 
2020). Approximately half a million people fall ill and 180,000 die from drug-resistant M. tb each 
year (Geneva: World Health Organization, 2020). The current vaccine available against TB is the 
Bacille Calmette-Guerin (BCG) vaccine, which is a live attenuated strain derived from 
Mycobacterium bovis (M. bovis)(Andersen and Doherty, 2005). This vaccine has its advantages 
and limitations. BCG is most commonly administered to infants soon after birth and is effective in 
protecting young children against severe forms of TB such as miliary TB and meningeal TB 
(Andersen and Doherty, 2005; Mattow et al., 2003). However, protectiveness of the vaccine 
against pulmonary TB is poor in adults (Andersen and Doherty, 2005). In addition, there is a wide 
range of variability in the protectiveness of BCG due to differences in culturing methods in 
laboratories worldwide (Andersen and Doherty, 2005; Davenne and Mcshane, 2016). Due to the 
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poor efficacy of BCG and the harsh treatments of TB, more research is needed on the pathogenesis 
of M. tb in order to develop an improved vaccine and treatment regimen. 
1.2. Pathogenesis of tuberculosis 
 M. tb enters the body through inhalation of aerosols and the bacterium travels through the 
lower respiratory tract to the alveoli (Lerner et al., 2015). Within the alveoli, M. tb is able to infect 
a variety of local and recruited immune cells in the alveoli including alveolar macrophages (AMs), 
dendritic cells (DCs), neutrophils, and type-2 airway epithelial cells (AECs) (Figure 1.2) (Lerner 
et al., 2015). Type-2 AECs infected by M. tb can act as an immune sentinel where they can activate 
mucosal-associated invariant T-cells and induce production of protective cytokines such as tumour 
necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), which are important for M. tb clearance (Lawn 
and Zumla, 2011; Lerner et al., 2015; de Martino et al., 2019). DCs are another type of immune 
cell that can be infected by M. tb and is crucial for bridging the innate immune response and the 
adaptive immune response (Barber-Mayer and Barber, 2015; Lerner et al., 2015; Poirier and Av-
Gay, 2012). Following uptake of M. tb, DCs process the surface antigens of the bacteria and present 
them on the DC surface via major histocompatibility complex I and II (MHC-I or II) to prime T-
Figure 1.2. M. tb infects multiple cell types in the alveoli. Within the alveoli, M. tb is able to infect several 
types of cells including AMs, DCs, neutrophils as well as type-2 AECs (Pai et al., 2016). 
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cells in local draining lymph nodes and initiate an adaptive immune response (Barber-Mayer and 
Barber, 2015; Lerner et al., 2015). Neutrophils play a role in enhancing M. tb killing by infected 
macrophages as well as modulating DC trafficking to the draining lymph node in order to prime 
CD4+ T-cells (Barber-Mayer and Barber, 2015). 
 Following DC migration into the lymph node, DCs prime naïve CD4+ T cells through 3 
signals: antigen presentation via MHC, costimulatory signal and a cytokine signal, interleukin- 12 
(IL-12) (de Martino et al., 2019). The CD4+ T cells then undergo activation and expansion of T 
cells specific against M. tb antigens and produce IFN-γ (de Martino et al., 2019). IFN-γ plays a 
key role in controlling M. tb infection and its production heavily relies on CD4+ T cells and some 
CD8+ T cells (de Martino et al., 2019). In turn, this can lead to M. tb evasion of the immune 
response, formation of granulomas and the development of latent disease (de Martino et al., 2019). 
Mounting an adaptive immune response can either be protective or damaging (Barber-Mayer and 
Barber, 2015). It is evident that in HIV co-infected patients, the lack of CD4+ T cells leads to the 
inability to control M. tb infection (Barber-Mayer and Barber, 2015). Alternatively, in HIV 
negative patients, CD4+ T cells can also mediate immunopathology and lung tissue damage 
(Barber-Mayer and Barber, 2015). Currently, an immune response that is protective against M. tb 
is not fully understood. However, it appears that a balance of both innate immunity and adaptive 
immunity is necessary. 
1.2.1. M. tb subversion of innate immunity in macrophages  
 AMs are one of the first immune cells that M. tb encounters when infecting the lungs. The 
macrophages use cell surface receptors to recognize antigens on the surface of M. tb as pathogen 
associated molecular patterns for internalization of the bacteria into a phagosome (Dey and Bishai, 
2014; Glickman and Jacobs, 2001; Lerner et al., 2015). After internalization of the bacteria, the 
phagosome interacts with the endosomal pathway where each step enables the phagosome to 
acquire endocytic and membrane components to progress the phagosomal maturation process 
(Figure 1.3) (Poirier and Av-Gay, 2012). These acquired components include vesicular-H+-
ATPase (V-ATPase), proteolytic enzymes (lysosomal hydrolases) and initiation of reactive 
oxygen species production (Poirier and Av-Gay, 2012). This results in the degradation of the 
bacteria and the antigens are processed by the macrophage for presentation (Poirier and Av-Gay, 
2012). Markers of phagosomal maturation include Rab7, Rab9, lysobisphosphatidic acid,  
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Figure 1.3. Steps of phagosomal maturation in macrophages. Phagocytosis of a foreign bacteria 
by a macrophage leads to interaction of the compartment with early endosomes, late endosomes, 
and lysosomes to result in phagosome maturation and ultimately elimination of the bacteria, 
processing and presentation of bacterial antigens. However, infection with M. tb results in 
premature arrest of phagosome maturation, leading to bacterial escape into macrophage cytosol 
(Poirier and Av-Gay, 2012). 
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mannose-6-phosphate receptor and lysosomal-associated membrane proteins (Poirier and Av-Gay, 
2012; Vieira et al., 2002).  
 In turn, M. tb is able to subvert the macrophage response in several ways: 1) escape the 
phagosome and take over the cell as its replicative niche, 2) modulate host cell type-1 IFN 
signaling, 3) downregulate autophagy and prevent antigen presentation, and 4) reprogram host cell 
death (Stutz et al., 2017). M. tb is able to escape bacterial killing by the macrophage by disrupting 
the phagosomal membrane and inhibiting phagosomal maturation (Gröschel et al., 2016; Stutz et 
al., 2017). It was shown that phagosomes containing M. tb did not fuse with lysosomes as markers 
of phagosomal maturation were absent in infected macrophages (Poirier and Av-Gay, 2012). M. 
tb is able to utilize its early secretory antigenic target-6 (ESAT-6) system-1 (ESX-1) secretion 
apparatus to escape the phagosome and mediate virulence (Gröschel et al., 2016). One particular 
way that M. tb may be able to halt phagosome maturation is to disrupt the V-ATPase acquired by 
the phagosome (Gröschel et al., 2016). In addition, it was found in M. marinum that two ESX-1 
secreted substrates, EsxA and EsxB, (also known as early secretory antigenic target-6 (ESAT-6) 
and culture filtrate protein-10 (CFP-10) respectively) were involved in breaching the phagosomal 
membrane and enabling escape of the bacteria (Gröschel et al., 2016; Tan et al., 2006). In doing 
so, M. tb is able to survive in the macrophage and avoid antigen processing and presentation 
required to initiate an adaptive immune response (Poirier and Av-Gay, 2012). 
 A critical step in the phagosomal maturation process that M. tb disrupts is the acidification 
of the phagosome through recruitment of the V-ATPase (Gröschel et al., 2016; Stutz et al., 2017). 
This enables M. tb to utilize its host cell as its replicative niche (Stutz et al., 2017). M. tb infection 
was also found to inhibit host-protective cytokines, dampening IFN-γ response, and induce 
immunosuppressive interleukin-10 (IL-10) (Stutz et al., 2017). The host cell also uses autophagy 
in order to remove and degrade damaged organelles (Bento et al., 2016; Huang and Bao, 2016). In 
addition, autophagy induced by IFN-γ can overcome disruption of the phagosomal maturation 
process by M. tb (Huang and Bao, 2016). However, it was found that M. tb downregulates 
autophagy possibly through inhibition of IFN-γ by an ESX-1 substrate, ESX-specific protein B 
(EspB) (Huang and Bao, 2016). M. tb is also able to manipulate antigen presentation by impairing 
DC maturation which can lead to the delay of adaptive immunity (Stutz et al., 2017). As a defence 
against M. tb infection, the host cell attempts to contain the bacteria within the phagosome, form 
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cytoplasmic blebs and enable uptake of the apoptotic cell by other phagocytes in order to prevent 
the spread of the pathogen (Elmore, 2007; Stutz et al., 2017). However, M. tb is able to upregulate 
anti-apoptotic proteins B cell lymphoma-2 and myeloid cell leukemia-1 (Spier et al., 2019). 
Additionally, M. tb was found to induce necrotic death of the host cell by causing mitochondria l 
damage and fragmentation (Spier et al., 2019; Wiens and Ernst, 2016). Induction of necrotic cell 
death in the host cell is beneficial for M. tb as the integrity of the host cell membrane is lost and 
can promote extracellular spread of M. tb (Moraco and Kornfeld, 2014). 
1.3. M. tb ESX secretion systems 
 Due to the thick mycobacterial cell envelope, specialized secretion systems called ESX 
systems are utilized in mycobacteria for transport of substrates across the cell envelope (Gröschel 
et al., 2016; Houben et al., 2012). These ESX systems are present in mycobacteria and other genera 
within the Actinobacteria phylum (Gröschel et al., 2016). There are similarities in all of the esx 
loci in that they contain genes encoding small secreted proteins approximately 100 amino acids in 
length (Gröschel et al., 2016). These proteins contain a conserved Trp-X-Gly (WxG) motif 
involved in the helix-turn-helix structure as well as a secretion signal that is present in many of 
these proteins (Gröschel et al., 2016; Houben et al., 2014). The ESX systems are comprised of 
several groups of proteins: core ESX-conserved component (Ecc) proteins that are structural 
transmembrane components that assemble into the secretion machinery, accessory ESX-specific 
proteins (Esp) that are secreted virulence effectors, and a conserved mycosin protein (MycP), 
which is a subtilisin serine-like protease involved in substrate processing and regulation of ESX 
secretion (Gröschel et al., 2016; Houben et al., 2014; Ohol et al., 2010; Stoop et al., 2012). Despite 
these similarities, the functions of the ESX systems can vary greatly. 
 At least 3 of the 5 ESX systems are required for full virulence of M. tb, namely: ESX-1, 
ESX-3, and ESX-5 (Gröschel et al., 2016). The ESX-3 system is involved in mycobactin-mediated 
iron acquisition, whereas the ESX-5 system is involved in secretion of Pro-Glu (PE) and Pro-Pro-
Glu (PPE) proteins required for immune evasion and virulence of M. tb (Beckham et al., 2017; 
Gröschel et al., 2016). The ESX-3 system is conserved among many mycobacterial species and 
plays an important role in the viability of both environmental and pathogenic mycobacteria 
(Gröschel et al., 2016). Expression of the esx-3 genes are dependent on the presence of iron or zinc 
which demonstrates its role in metal acquisition and metabolism (Gröschel et al., 2016). Its 
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importance in bacterial growth was determined by the inability to recover M. tb strains deficient 
in ESX-3 for many years (Gröschel et al., 2016). In addition to its role in metal homeostasis, ESX-
3 appears to be important during infection (Gröschel et al., 2016). EsxH secreted by the ESX-3 
system strongly induces IFN-γ secretion in T-cells (Gröschel et al., 2016). It is also able to interact 
and disrupt the endosomal sorting complex required for transport (ESCRT) of the infected host 
cell (Gröschel et al., 2016). The ESX-1 and the ESX-5 secretion systems share similar core 
structural proteins that were shown to have approximately 30% amino acid identity (Beckham et 
al., 2017; Gröschel et al., 2016). Therefore, , determining the structure of the ESX-5 system may 
provide more information on the structure and assembly of the ESX-1 system (Beckham et al., 
2017). 
 In contrast to the 3 aforementioned ESX systems, the functions of the ESX-2 and ESX-4 
systems are largely unknown. Given that Mycobacterium leprae and Mycobacterium lepromatosis 
have lost their esx-4 locus and have a non-functional ESX-2 system, it appears that these ESX 
systems are not essential for in vivo growth or virulence of mycobacteria (Gröschel et al., 2016). 
1.3.1. M. tb type-7 ESX-1 secretion system 
 The type-7 ESX-1 system is the most well studied of the 5 ESX systems present in M. tb. 
Using this secretion system, M. tb is able to disrupt phagosomal maturation and evade killing 
(Chen et al., 2013). Through comparison studies between BCG and M. tb, it was shown that BCG 
was lacking a region of difference (RD-1), which was present in M. tb as the esx-1 locus (Gröschel 
et al., 2016; Kroesen et al., 2019). The key functions of the ESX-1 secretion system includes 
phagosomal rupture, which enables the release of the pathogen into the cytosol (Gröschel et al., 
2016; Simeone et al., 2012). In addition, it is involved in host cell invasion, intracellular 
replication, cellular inflammation, host-cell death, and dissemination of the bacteria (Chen et al., 
2013). The ESX-1 secretion machinery is assembled by core Ecc proteins and is able to secrete 
virulence effectors such as Esx and Esp proteins (Gröschel et al., 2016; Stoop et al., 2012). In 
addition, MycP1 is also a part of the ESX-1 system that is responsible for substrate processing and 
secretion regulation (Gröschel et al., 2016). 
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1.4. ESX-1 secreted effectors 
 The ESX-1 system is encoded by the esx-1 locus as well as an upstream espACD operon 
(Figure 1.4) (Gröschel et al., 2016). These genes include the core Ecc proteins as well as accessory 
Esp proteins. Core Ecc proteins of the ESX-1 system including EccC, EccB, EccD, and EccE 
assemble into the ESX-1 secretion machinery (Figure 1.5) (Gröschel et al., 2016; Stoop et al., 
2012). The ESX-1 system shares some of these core components with the ESX-5 system with 
approximately 30% identical amino acids, and therefore structural studies of the ESX-5 system 
may be useful in determining the assembly and structure of the ESX-1 system (Gröschel et al., 
2016). Two of the main ESX-1 substrates, EsxA and EsxB, are crucial for the full virulence of M. 
tb (Forrellad et al., 2013; Gröschel et al., 2016; Simeone et al., 2009). It was shown that EsxA and 
EsxB are co-secreted by the bacterium as homo- and hetero-dimers and were found to dissociate 
under acidic conditions, allowing EsxA to induce pores in the phagosomal membrane (Chen et al., 
2013; Forrellad et al., 2013; Ma et al., 2015; Zhang et al., 2016). This was further confirmed as M. 
tb that is defective in EsxA is unable to disrupt phagosomal maturation of the infected host cell, 
leading to bacterial clearance (Wong, 2017). 
 Other secreted virulence factors are the Esp proteins, some of which are encoded on the 
esx-1 locus itself, whereas others are encoded on the upstream espACD operon (Forrellad et al., 
2013; Gröschel et al., 2016). As with EsxA and EsxB, these secreted effectors are shown to be 
interdependent with each other, which demonstrates how complex the ESX-1 secretion system is 
(Gröschel et al., 2016). For instance, EspA and EspC are co-secreted with EsxA and EsxB (Chen 
et al., 2013; DiGiuseppe Champion et al., 2009). Furthermore, EspC interacts with the ESX-1 core 
Figure 1.4. The esx-1 locus and upstream espACD operon encode genes that make up the 
ESX-1 secretion system of M. tb. The ΔRD1
BCG
 indicate the genes that are absent in BCG 
(Gröschel et al., 2016). 
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components to facilitate the secretion of EsxA and EsxB (Chen et al., 2013; DiGiuseppe Champion 
et al., 2009). EspD secretion was shown to be largely ESX-1 independent, but its expression is 
required for EsxA and EsxB secretion, as well as stabilizing the intracellular levels of EspA and 
EspC (Chen et al., 2012, 2013). Expression of EsxB is also required for EspB expression and 
secretion (Chen et al., 2013). During EspB secretion, it also interacts with MycP1 for processing 
of its C-terminus end (Chen et al., 2013; Ohol et al., 2010). 
1.4.1. PE/PPE proteins of M. tb 
 The ESX systems from mostly pathogenic mycobacterial species are known to secrete 
proteins that are a part of the PE/PPE protein family (Daleke et al., 2012). Approximately 10% of 
Figure 1.5. Assembly of the ESX-1 secretion system of M. tb. This schematic shows a working 
model of the assembly of the core Ecc proteins and secretion of Esx and Esp proteins from the 
ESX-1 secretion system.  
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the M. tb genome is made up of pe and ppe genes, whereas non-pathogenic mycobacteria were 
reported to encode fewer pe/ppe genes in comparison (Ekiert and Cox, 2014). These are small 
proteins that serve a variety of functions such as nutrient transport, pathogenesis of TB, and 
possibly antigenic variability of M. tb (Ekiert and Cox, 2014; Majlessi et al., 2015; Solomonson et 
al., 2015; Wang et al., 2020). Consistent with the interdependency between the ESX substrates, 
PE/PPE proteins were shown to interact with other ESX substrates (Ekiert and Cox, 2014). For 
example, EspG of the ESX-5 system was shown to be a chaperone for the PE25/PPE41 complex 
to prevent self-aggregation of the PE/PPE proteins (Ekiert and Cox, 2014; Solomonson et al., 
2015). In addition, many of these PE/PPE proteins are associated with the outer layer of the 
mycobacterial cell envelope for a variety of functions including nutrient transport (Ekiert and Cox, 
2014; Wang et al., 2020). Interestingly, PE and PPE proteins appear to be only stable in a PE/PPE 
complex (Strong et al., 2006). Other Esx and Esp proteins also have structures resembling PE/PPE 
and can similarly form homo- or hetero-dimeric complexes (Solomonson et al., 2015). For 
example, EsxAB heterodimer and monomeric EspB have structures resembling the PE25/PPE41 
complex (Solomonson et al., 2015). Therefore, studies of these PE/PPE structures may be helpful 
in determining structures of other ESX-1 substrates. 
1.5. EspB 
 The protein of interest in this project is EspB which is expressed and secreted through the 
ESX-1 secretion system. EspB is expressed as a 60 kDa protein within the bacterium and is cleaved 
during its secretion by MycP1 into 50 kDa (Ohol et al., 2010). Truncation of EspB is required for 
full virulence of M. tb (Solomonson et al., 2015). It was shown that the cleaved C-terminus of 
EspB has roles in regulating ESX-1 secretion, such as maintaining intracellular levels of EsxA and 
secretion of EsxA and EsxB (Ohol et al., 2010; Solomonson et al., 2015). EspB was also shown to 
interact with the C-terminal region of EspK, where EspK may be serving as a chaperone 
(McLaughlin et al., 2007; Mishra et al., 2019). This further demonstrates the interconnectedness 
of the ESX-1 substrates. However, the functions of both intracellular and secreted EspB is 
currently unclear. 
1.5.1. Prior characterization of EspB and identification of its distinct virulence functions 
 Two previously published M. tb transposon mutants: M. tb espA::Tn and M. tb 5’Tn::pe35  
were constructed and studied (Chen et al., 2012, 2013). These mutants contain a single Tn5370 
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transposon insertion at the espA gene (espA::Tn) or upstream of the pe35 gene (5’Tn::pe35) (Chen 
et al., 2013). The M. tb espA::Tn mutant was found to be deficient in EspA, EspC, and EspD 
expression and was unable to secrete EsxA and EsxB (Chen et al., 2012, 2013). Whereas, the M. 
tb 5’Tn::pe35 mutant was found to have lower mRNA levels of pe35, ppe68, esxB, esxA, espI, and 
eccD1, leading to the shutdown of the ESX-1 secretion system (Brodin et al., 2006; Chen et al., 
2013) Both transposon mutants were found to be disrupted in the functionality of their ESX-1 
systems when infecting THP-1 macrophages (Figure 1.6) (Chen et al., 2013). In comparison to 
WT M. tb infected macrophages, both transposon mutants induced lower levels of cytotoxicity 
(Chen et al., 2013). However, M. tb espA::Tn was able to induce higher levels of cytotoxicity 
compared to M. tb 5’Tn::pe35 (Chen et al., 2013). The phenotypes of these transposon mutants 
were demonstrated in both THP-1 cells and MRC-5 cells with consistent results (Chen et al., 2013). 
 Interestingly, upon analyzing the secretion profiles of the transposon mutants using culture 
filtrate (CF) and cell lysate (CL), the M. tb espA::Tn mutant was revealed to express and secrete 
EspB whereas M. tb 5’Tn::pe35 was able to express but not secrete EspB (Figure 1.7) (Chen et al., 
Figure 1.6. Percent relative cytotoxicity of M. tb strains infecting THP-1 macrophages. THP-
1 macrophages were infected with WT M. tb, M. tb espA::Tn, or M. tb 5’Tn::pe35 (Chen et al., 
2013).  
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2013). In addition, M. tb espA::Tn expressed but did not secrete EsxA and EsxB, whereas the M. 
tb 5’Tn::pe35 lacked expression of both EsxA and EsxB (Chen et al., 2013). This also revealed 
that disruption of EsxA and EsxB expression blocks EspB secretion but not its expression (Chen 
et al., 2013).  
 Addition of purified mature (50 kDa) EspB with M. tb 5’Tn::pe35 mutant to infect THP-1 
macrophages restored the virulence of this strain to the same level as M. tb espA::Tn mutant (Figure 
1.8) (Chen et al., 2013). However, addition of purified EspB to THP-1 macrophages without the 
presence of bacteria was not able to induce cytotoxicity (Chen et al., 2013). This demonstrates that 
EspB was responsible for the gap in virulence between M. tb espA::Tn and M. tb 5’Tn::pe35 strains 
and that the presence of M. tb is essential for the virulence function of EspB (Chen et al., 2013). 
This study revealed that EspB has a distinct virulence function independent of EsxA and EsxB, 
which prompted further investigation on how secreted EspB functions to induce cytotoxicity in 
THP-1 macrophages.  
 
Figure 1.7. Secretion profile analysis of WT M. tb, M. tb espA::Tn, and 5’Tn::pe35. A 
western blot of the secreted proteins in the culture filtrate (CF) and expressed proteins in the cell 
lysate (CL) was performed (Chen et al., 2013). 
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1.5.2. Structure of EspB 
 The structure of secreted EspB (50 kDa form) was recently solved by two independent 
research groups. The primary structure of EspB consists of a PE and PPE domain with a linker in 
between (Figure 1.9) (Solomonson et al., 2015). The monomer assembles into a PE/PPE-like fold 
that resembles the structure of PE25/PPE41 from the ESX-5 system (Solomonson et al., 2015). 
This hairpin-like structure is stabilized by a WxG and Tyr-x-x-x-Asp (YxxxD) motif, which also 
serves as a bipartite secretion signal (Piton et al., 2020; Solomonson et al., 2015). Residues in the 
export arm of EspB were shown to be identical to the sequence in EsxBTB that is essential for 
interaction with EccCb1 (Solomonson et al., 2015). Mutation of the YxxxD motif or deletion of 
EccCb1 was found to disrupt EspB secretion (Solomonson et al., 2015). In addition, two 
hydrophobic pockets were identified on the EspB monomer that was predicted to bind the fatty 
acid regions of phospholipids (Korotkova et al., 2015). The residues within the hydrophobic 
Figure 1.8. Addition of purified mature EspB to M. tb 5’Tn::pe35 induces cytotoxicity to M. 
tb espA::Tn levels in THP-1 macrophages. Various concentrations of purified mature EspB 
(EspBcut) or denatured EspB (dnEspBcut) added to M. tb 5’ Tn::pe35 to infect THP-1 
macrophages. Compared to cytotoxicity induced by WT M. tb, M. tb espA::Tn or EspB alone 
infecting THP-1 macrophages (Chen et al., 2013). 
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pockets were identified at helices α1 and α2 (L60, F159, and L163) and helices α6 and α7 (L232, 
I246, Y236, and Y250) (Figure 1.10) (Korotkova et al., 2015). 
 
Figure 1.9. Schematic of EspB protein domains and structure of EspB oligomer. EspB 
contains a PE and PPE domain with a linker in between the YxxxD and WxG motif. The protein 
assembles into a heptameric oligomeric structure (Piton et al., 2020). 
Figure 1.10. Hydrophobic grooves identified on EspB monomer.  Hydrophobic grooves on the 
EspB monomer are indicated as α1- α2 groove and α6- α7 groove (Korotkova et al., 2015) 
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1.5.3. EspB binds phospholipids 
 EspB was previously shown to bind acidic phospholipids, specifically phosphatidic acid 
(PA) and phosphatidylserine (PS) (Chen et al., 2013). It was shown that purified mature EspB 
bound to PA and PS on a lipid membrane overlay assay (Figure 1.11) (Chen et al., 2013). Whereas 
purified, unprocessed EspB did not bind to PA or PS on the lipid spotted membrane (Chen et al., 
2013). However, the residues within EspB responsible for binding these phospholipids are 
currently unknown. Since PA and PS play important roles in the mammalian host cell, it is possible 
that phospholipid binding plays a role in the virulence function of EspB. 
 Given that M. tb is able to induce mitochondrial damage of the host cell during infection, 
it is possible that interactions of EspB with PA on the mitochondrial membrane can contribute to 
mitochondrial damage. PA was shown to have important roles in regulating mitochondrial fusion  
and fission (Yang and Frohman, 2012). Mitochondrial fusion is important in energy production of 
the cell and fission allows for damaged mitochondrial components to be recycled via autophagy 
(Yang and Frohman, 2012). Therefore, interaction of EspB with PA may interfere with PA 
regulation of mitochondrial fission and fusion. In addition, as M. tb is able to induce mitochondria l 
damage as well as downregulate autophagy by the host cell, this collectively disrupts with the 
defence mechanisms of the host cell.  
 One of the signals of an apoptotic cell is PS on the outer leaflet of the cell membrane 
(Bohdanowicz and Grinstein, 2013). PS is primarily localized at the inner leaflet of mammalian 
cells but when exposed to the outer leaflet, it serves as an “eat me” signal for uptake by other 
phagocytes (Bohdanowicz and Grinstein, 2013). As discussed above, apoptosis is one of the 
defense mechanisms that macrophages utilize to contain the bacteria and prevent spread of the 
infection (Spier et al., 2019). It is possible that M. tb uses its ESX-1 effectors to interact and inhibit 
PS exposure to the outer leaflet and disrupting this apoptotic signal.  
 In addition to mitochondrial damage and inhibition of apoptosis, M. tb infection also causes 
disruption in the phagosomal maturation process. The process of phagocytosis and phagosomal 
maturation involves many precisely coordinated steps of membrane trafficking and recruitment of 
components to facilitate in the acidification of the compartment (Bohdanowicz and Grinstein, 
2013). Soon after phagocytosis of the pathogen, phosphatidylinositol 3-phosphate (PI(3)P) 
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accumulates at the phagosomal membrane and plays a critical role in the maturation process of 
phagosomes (Levin et al., 2015). Therefore, disruption of this phospholipid may lead to failure to 
accumulate PI(3)P to the phagosomal membrane, resulting in its arrest in an immature state (Levin 






Figure 1.11. Purified mature EspB binds to PA and PS. Mature EspB (EspBcut) was shown to 
bind to PA and PS using A. membrane lipid overlay strips and B. arrays containing decreasing 
concentration of phospholipids spotted on the membrane. Whereas unprocessed EspB (EspBFull) 
did not bind to the phospholipids (Chen et al., 2013). 
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2. Rationale, Hypothesis, and Objectives 
2.1. Rationale  
 EspB was shown to be able to induce cytotoxicity in macrophages with the presence of M. 
tb (Chen et al., 2013). This was demonstrated by the addition of purified EspB to M. tb 5'Tn::pe35 , 
which resulted in induction of cytotoxicity in infected macrophages to the same level as M. tb 
espA::Tn (Chen et al., 2013). In addition, EspB was found to bind to phospholipids (Chen et al., 
2013). The interaction was demonstrated to be specific to PA and PS which are important for 
macrophage function (Chen et al., 2013). Furthermore, structural studies revealed potential PA 
and PS binding domains on EspB (Korotkova et al., 2015). These studies also showed that EspB 
adopts a heptameric barrel oligomer (Korotkova et al., 2015; Piton et al., 2020; Solomonson et al., 
2015). Collectively, these data lead to the hypothesis that the virulence function of EspB may be 
dependent on its ability to bind phospholipids (PA and PS). Additionally, oligomerization of EspB 
may play an important role in its ability to interact with phospholipids. Therefore, the goal of this 
project was to further characterize the phospholipid interactions and oligomerization of EspB and 
how these relate to its virulence function. 
2.2. Hypothesis 
 The distinct virulence property of secreted EspB in its 50 kDa mature form is dependent 
on phospholipid binding. 
2.3. Objectives 
 1. I will construct EspB variants containing mutations in residues predicted to be important 
for EspB function. The constructed variants will be characterized using phospholipid binding 
assays and oligomerization assays to determine if these phenotypes are critical for the virulence 
function of EspB. 
 2. The EspB variants will be added to the M. tb 5’ Tn::pe35 strain to infect THP-1 
macrophages to assess their ability to enhance cytotoxicity of the macrophages. Cell viability will 




3. Materials and Methods 
3.1. Mapping of targeted residues on 3D model of EspB 
 Molecular graphics and analyses were performed using the UCSF Chimera program 
developed by the Resource for Biocomputing, Visualization, and Informatics team at the 
University of California, San Francisco, with support from NIH P41-GM103311 (Pettersen et al., 
2004). The 3D structural file of EspB was obtained from the protein data bank (PDB) (access 
number 6XZC) from a previously published structural paper (Piton et al., 2020). The PDB file was 
opened using the UCSF Chimera 1.13.1 molecular modelling system. Residues that were targeted 
for mutagenesis were labelled with the residue one letter code and position number. These residues 
were also colour coded for clarity. Each EspB variant that were labelled and colour coded were 
saved as separate files. 
3.2. Construction of espB mutations 
 The variants espBR17A/H223A and espBK259A/K267A were constructed by site-directed 
mutagenesis of the espBWT gene that was already cloned into pET28a plasmid. The variants 
espBW176R and espBF159R/I246R on the other hand, were synthesized and cloned into a vector, 
pUCIDT (KanR) by Integrated DNA Technologies (IDT). The forward and reverse primers used 
for each variant are summarized in Table 1. All EspB variants that were constructed in this project 
contained a 6X His-tag and was not removed after purification. Experimental details are described 
below. 
Table 1: Primers used for espB variant constructs. 
Mutation Direction Primers used for Plasmid Constructs  
WT  Forward 
Reverse 
5’ – CAG CAT ATG ACG CAG TCG CAG ACC GTG ACG GTG – 3’ 
5’ – CGC CTC GAG TCA CGG GAG GCC ACC ACC CGG CGA TCC – 3’ 
R17 → A Sense 
Anti-sense 
5’ – GAG ATT TTG AAC GCG GCC AAC GAG GTG – 3’ 
3’ – CTC TAA AAC TTG CGC CGG TTG CTC CAC – 5’  
H223 → A Sense 
Anti-sense 
5’ – GCA AGG CGG GAA GCT CCG ACT TAT GAA – 3’ 
3’ – CGA TCC GCC CTT CGA GGC TGA ATA CTT – 5’ 
F159 → R Sense 
Anti-sense 
5’ – GGG TGG AAC ACT CGC AAC CTG ACG CTG – 3’ 
3’ – CCC ACC TTG TGA GCG TTG GAC TGC GAC – 5’ 
I246 → R Sense 
Anti-sense 
5’ – GCC CGC GAC CAA CGT CTC CCG GTG TAC – 3’ 
3’ – CGG GCG CTG GTT GCA GAG GGC CAC ATG – 5’  
K259 → A Sense 
Anti-sense 
5’ – CAG AGG TCG GAG GCG GTG CTG ACC GAA – 3’ 
3’ – GTC TCC AGC CTC CGC CAC GAC TGG CTT – 5’ 
K267 → A Sense 5’ – GAA TAC AAC AAC GCG GCA GCC CTG GAA – 3’ 
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Anti-sense 3’ – CTT ATG TTG TTG CGC CGT CGG GAC TTC – 5’ 
 
3.2.1. Site-directed mutagenesis 
 The espBWT gene fragment corresponding to the secreted isoform had been previously 
cloned into the pET28a plasmid (Chen et al., 2013). Site directed mutagenesis of the espBWT gene 
was performed using Q5® Site-Directed Mutagenesis Kit (New England BioLabs). Annealing 
temperatures of the PCR cycles were adjusted to 3-5 °C lower than the melting temperatures of 
the primers that were used. Site-directed mutagenesis for a single residue replacement was first 
performed. The plasmid was purified from PCR products using Monarch® Plasmid Mini-Prep Kit 
(New England Biolabs) and quantified using NanoDrop™ OneC Spectrophotometer (Thermo 
Scientific). The purified plasmid was then transformed into TOP10 E. coli to prepare a larger 
quantity of plasmids. The plasmid with a single residue change was then used as a template for a 
second site-directed mutagenesis to construct a double mutant. PCR products were purified once 
again and transformed into TOP10 E. coli for higher yield plasmid preparation. The transformants 
were sequenced by Eurofins Genomics to confirm the mutations introduced into the espB gene.  
Table 2: Parameters of site-directed mutagenesis to construct espB variants. 
Segment Cycles Temperature (°C) Time  
1 1 98  2 minutes 
2 18 98 30 seconds 
espBR17A/H223A – 67 
espBK259A/K267A – 61  
1 minute 
72 15 minutes 
3 1 18 Hold 
 
3.2.2. Ligation of synthesized espB into pET28a 
 The variants espBF159R/I246R and espBW176R were commercially synthesized into a pUC19-
based vector pUCIDT (KanR) by IDT with the addition of an NdeI cut-site at the C-terminus and 
an XhoI cut-site at the N-terminus of the gene. The plasmid was used for a double restriction digest 
with NdeI and XhoI (New England Biolabs). Next, 1 μL of each enzyme was added to 1 μL of the 
plasmid with 5 μL of 10X CutSmart Buffer (New England Biolabs). Water was added to the 
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mixture to a total volume of 50 μL. The double restriction digest was also performed on pET28a 
plasmid. The mixture was incubated for 2 hours at 37 °C, then was heated to 65 °C for 20 minutes 
for heat inactivation of the enzymes. The digests were resolved on a 0.8% agarose gel and the espB 
gene was excised from the gel for purification using the Monarch® DNA Gel Extraction Kit (New 
England Biolabs) according to manufacturer’s instructions. The digested pET28a plasmid was also 
resolved and excised from the agarose gel for purification using the same kit. The purified espB 
gene and the cut pET28a plasmid was used for ligation using the T7 ligase (New England Biolabs). 
The ligation was performed using a molar ratio of 1:3 vector (pET28a) to purified DNA insert 
(espB gene) in 10 μL of 2X T7 DNA ligase reaction buffer (New England Biolabs) with 1 μL of 
T7 DNA ligase. Water was added to the mixture to a total volume of 20 μL. The mixture was 
incubater at room temperature for 30 minutes, then chilled on ice prior to transformation into 
TOP10 E. coli. 
3.2.3. Preparation of plasmids  
 The constructed pET28a vectors containing the espB gene variants were transformed into 
TOP10 chemically competent E. coli (Invitrogen) for plasmid propagation and long-term storage. 
Heat shock transformation was performed by first adding 3 μL of purified plasmid or 10 μL of 
PCR products into a tube containing 50 μL of TOP10 E. coli and incubated on ice for 20 minutes. 
The mixture was heat shocked at 42 °C for 40 seconds and transferred back onto ice for 2 minutes. 
Then, 500 μL of fresh SOC media was added to the mixture and incubated at 37 °C for 1 hour with 
continuous shaking at 200 rpm. The culture was centrifuged at maximum speed and the pellet was 
resuspended with 100 μL of the LB media and plated on LB agar containing 50 μg/mL of 
kanamycin. The transformants were used to inoculate 10 mL of LB media containing 50 μg/mL of 
kanamycin and allowed to grow overnight at 37 °C, with continuous shaking at 200 rpm. The 
culture was centrifuged to harvest the cells. The pellet was obtained for plasmid purification using 
Monarch® Plasmid Miniprep Kit (New England BioLabs) following the manufacturer’s 
instructions. The plasmid concentration was quantified using NanoDrop™ 
OneC Spectrophotometer (Thermo Scientific). 
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3.3. Purification of EspB 
3.3.1. Transformation of pET28a into E. coli for recombinant EspB production 
 A volume of 3 μL of purified pET28a plasmid containing espB was added to 100 μL of 
chemically competent low background strain (LOBSTR) BL21 (DE3) E.coli and incubated on ice 
for 20 minutes. The mixture was then heat shocked at 42 °C for 40 seconds and placed back onto 
ice for 2 minutes. LB media was added to 500 μL to the bacterial cells and allowed to recover at 
37 °C, with continuous shaking at 200 rpm for 1 hour. The recovered cells were plated onto LB 
agar containing 50 μg/mL of kanamycin and incubated at 37 °C overnight. 
3.3.2. Growth and induction of cultures  
 The transformants were used to inoculate 200 mL of LB media and incubated at 37 °C, 
with agitation at 200 rpm for 12 hours (overnight) to establish a starter culture. The starter culture 
was added to 1 L of LB media to an OD of 0.1 and allowed to incubate at 37 °C until the culture 
had reached an OD of 0.5. The E. coli in the culture was induced with 1 mM of IPTG to allow 
vector protein expression for 4 hours at 37 °C. When the culture reached an OD of 1, E. coli was 
harvested by centrifugation at 5000 rpm for 10 minutes. The harvested cell pellet was resuspended 
in 150 mL of LEW (Lysis-Equilibrium-Wash) buffer (150 mM NaCl, 50 mM NaH2PO4, at pH 8) 
and were lysed using the Avestin EmulsiFlex-C3 homogenizer at 15,000 psi for 3 cycles. The 
lysate was centrifuged at 19,000 rpm, 4 °C for 40 minutes to remove cellular debris. The pellet 
was discarded, and the clarified lysate was used for further purification.  
3.3.3. Ammonium sulfate precipitation 
 Ammonium sulfate ((NH4)2SO4) (Sigma-Aldrich) was added to the clarified lysate 5% 
increments until a final saturation of 50% was reached (Table 3). The lysate was centrifuged at 
10,000 rpm for 10 minutes to recover any precipitated protein after every addition of (NH4)2SO4. 
The pellets collected from each fraction were resuspended in LEW buffer and resolved on an SDS-
PAGE (Invitrogen) to confirm the presence of EspB in the pellets. The fractions that contained 
EspB were further diluted into 10 mL of LEW buffer prior to the next purification step. 
Table 3: (NH4)2SO4 added to 150 mL lysate at 25 °C 













3.3.4. Ni-IDA column purification 
 Nickel column purification was performed by adding 1 g of Protino Ni-IDA Resin 
(Macherey-Nagel) to fractions containing EspB diluted into 10 mL of LEW buffer. The slurry was 
allowed to incubate overnight at 4 °C with continuous shaking. The slurry was poured into the 
column and the flow-through was collected. The resin was washed with 10 mL of LEW buffer and 
LEW buffer with increasing concentration of imidazole (10 – 30 mM) (Sigma-Aldrich). The 
binding protein was then eluted with LEW containing 250 mM or 500 mM imidazole. Each elution 
was collected in separate centrifuge tubes. The collected fractions were analyzed on SDS-PAGE 
and elutions containing purified EspB were concentrated and buffer exchanged using Vivaspin 
concentrator spin columns (Sartorius) until a volume of 1.5 mL was reached. 
3.3.5. Quantification of purified EspB 
 Bovine serum albumin (BSA) standards were prepared at 500 μg/mL and diluted two-fold 
until the lowest concentration was at 31.25 μg/mL. The purified protein samples were diluted 1:10 
in LEW buffer. The BSA standards and protein samples were prepared at a final volume of 50 μL 
and was quantified using the BCA Protein Assay Kit (Pierce) according to manufacturer’s 
instructions. Quantified EspB samples were resolved on a SDS-PAGE gel. Equal amounts of 
purified EspB (10 μg) were added to NuPAGE™ 4 – 12% Bis-Tris gel (Invitrogen) and resolved 
at 200 V for 23 minutes. The gel was removed and stained with Coomassie blue. For antibody 
detection, 5 μg of EspB was resolved on the Bis-Tris gel using the same conditions. The gel was 
transferred onto a nitrocellulose membrane using the iBlot 2 Dry Blotting System (Invitrogen) at 
25 V for 7 minutes. The nitrocellulose membrane was blocked with 10 mL of 5% skim milk in 
tris-buffered saline (TBS) for 1 hour in room temperature with continuous shaking. The membrane 
was washed 3 times using TBS (with 2 minute shaking in between washes) and incubated with 10 
mL of 1:1,000 rat anti-EspB primary antibody in TBS with 0.05% TWEEN 20 (TBST) overnight 
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at 4 °C with continuous shaking. The next day, the membrane was washed 3 times with TBST and 
incubated with 1:10,000 IRDye® 800CW (fluorescently labelled) goat anti-rat secondary antibody 
(LI-COR Biotechnology) in TBST for 1 hour in room temperature. The membrane was washed 3 
times with TBST and imaged on Odyssey CLx imaging system (LI-COR Biotechnology). 
3.4. Native-PAGE  
 Purified EspB samples at 10 μg were prepared in 2X NovexTM Tris-Glycine Native Sample 
Buffer (Invitrogen) and water at a total volume of 40 μL. The samples were resolved on NovexTM 
WedgeWellTM 4- 12% Tris-Glycine protein gel (Invitrogen) at 4 °C for 2 hours at 80V. The gel 
was then rinsed with water and stained with Coomassie blue dye for 1 hour. The gel was destained 
overnight and was imaged on the Odyssey CLx imaging system (LI-COR Biotechnology). 
3.5. Dynamic light scattering 
3.5.1. EspB preparation 
 Purified EspB samples were filtered through 0.22 μm Costar Spin-X centrifuge tube filters 
(Corning) and were concentrated using 10k molecular weight cut-off (MWCO) Protein 
Concentrator Tubes (Pierce). A BCA assay was performed to quantify the concentration of the 
samples. The filtered and concentrated samples were prepared at a concentration of 2 mg/mL at 
50 μL and kept at 4 °C until ready for use. 
3.5.2. DLS measurement of EspB samples 
 Dynamic light scattering (DLS) analysis was performed at the Protein Characterization and 
Crystallization Facility (PCCF) which is supported by the College of Medicine, University of 
Saskatchewan, Saskatoon, Canada. This experiment was performed with the help of Dr. Michal 
Boniecki. The prepared samples were centrifuged at maximum speed for 5 minutes prior to DLS 
measurement of the samples. A volume of 50 μL was dispensed into the reading plate and inserted 
into the DynaPro Plate Reader II (Wyatt Technologies). Temperature of the instrument was set to 
20 °C, acquisition time was set to 1 and number of acquisitions was set to 60. The data was 
analyzed on the DYNAMICS Software (Wyatt Technologies). 
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3.6. Transmission electron microscopy procedure  
3.6.1. EspB preparation and staining 
 Purified EspB was diluted to 150 μg/mL in 500 μL of LEW buffer. Formvar/carbon coated 
copper grids were glow discharged with Quorum Q150T ES to make the surface of the grids 
hydrophilic. Next, 5 μL of sample was applied to the grid and allowed to be absorbed for 1 minute. 
The grid was washed with water for 20 seconds and stained with 2% uranyl acetate in water for 1 
minute. The excess staining solution was removed using filter paper and the grid was allowed to 
dry prior to microscopy. 
3.6.2. Microscopy procedure  
 Imaging of the prepared EspB samples were performed on the Hitachi HT7700 
transmission electron microscope with the help of Dr. Eiko Kawamura. After inserting the sample 
into the microscope, the beam was switched on and aligned to the center of the field of view. A 
region of the grid was selected to image and the focus and contrast were adjusted. Images in this 
project were captured at 100k magnification. 
3.7. Phospholipid binding assays  
3.7.1. Custom made phospholipid spotted membrane preparation procedure  
 Phospholipid sodium salts 1,2-dilauroyl-sn-glycero-3-phosphate (DLPA) and 1,2-
dipalmitoyl-sn-glycero-3-phosphoserine (DPPS) were purchased from Echelon Biosciences. The 
phospholipid sodium salts were dissolved in a mixture of 1:1:0.1 chloroform:methanol:water. The 
solubilized phospholipids were adjusted to a concentration of 80 μM and diluted two-fold until a 
concentration of 5 μM was reached. The mixtures were stored in -20 °C until ready for use. Next 
nitrocellulose membrane was soaked in phosphate buffered saline (PBS) briefly, then dried with 
Kimwipe before dispensing 5 μL spots onto the membrane. The spots were allowed to dry before 
blocking the membrane in PBS with 0.1% TWEEN® 20 (Sigma-Aldrich) (PBST) with 3% BSA 
for 1 hour. The membrane was processed in the same way as commercially produced phospholipid 
spotted membranes. 
3.7.2. Phospholipid membrane overlay assay 
 Phospholipid spotted membranes were purchased from Echelon Biosciences and the assay 
was performed according to manufacturer’s instructions. The membranes were incubated in PBST 
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with 3% BSA for 1 hour in room temperature with continuous shaking. Next, the membranes were 
incubated with 0.5 μg/mL of EspB in 10 mL of PBST with 3% BSA for 1 hour. The membranes 
were washed 3 times with PBST prior to incubating with 10 mL of 1:1,000 rat anti-EspB primary 
antibody in PBST for 1 hour in room temperature. The membranes were washed 3 times with 
PBST, then incubated in 10 mL of 1:10,000 secondary goat anti-rat antibody (fluorescently 
labelled) in PBST for 1 hour in room temperature. Lastly, the membranes were washed 3 times 
with PBST prior to imaging the membranes on the Odyssey CLx imaging system. 
3.7.3. Phospholipid coated bead pull-down assay 
 Phospholipid coated agarose beads were purchased from Echelon Biosciences. Agarose 
beads were washed with 300 μL of PBS with addition of 0.25% IGEPAL® CA-630 (Sigma 
Aldrich) twice, centrifuged at 800 xg for 2 minutes in between washes. The wash buffer was 
removed and the beads were incubated with 1.5 μg of purified EspB in PBS with 0.25% IGEPAL® 
CA-630 overnight at 4 °C with continuous shaking. The next day, the beads were washed with 300 
μL of washing buffer (PBS + 0.25% IGEPAL® CA-630) and centrifuged at 800 xg. Washes were 
repeated 4 times before removing most of the wash buffer, leaving approximately 20 μL in the 
sample tubes for elution. The bound protein was eluted with 2% 2-mercaptoethanol in NuPAGE™ 
LDS Sample Buffer (Invitrogen) and boiled at 100 °C for 15 minutes. The eluted protein and the 
beads were transferred into Costar 0.45 μM SpinX tubes (Corning) and centrifuged the samples at 
maximum speed to remove beads from the eluted sample. The elution was resolved on the 
NuPAGE™ 4 – 12% Bis-Tris gel system and a western blot was performed as previously 
described. 
3.8. THP-1 macrophage infection 
3.8.1. M. tb culture preparation 
 M. tb frozen glycerol stocks (-80 °C) of WT M. tb Erdman was streaked out on Difco 7H11 
(Becton-Dickinson) agar plates supplemented with Middlebrook oleic albumin dextrose catalase 
(OADC) enrichment (Becton-Dickinson). The transposon mutant strains M. tb espA::Tn and M. tb 
5’Tn::pe35 were streaked out on 7H11 agar supplemented with OADC and containing 50 μg/mL 
hygromycin. The plates were incubated at 37 °C for approximately 2 weeks or until isolated 
colonies could be observed and picked for further culture in liquid media. A starter culture in liquid 
media was prepared by inoculating 10 mL of complete Difco Middlebrook 7H9 media (Becton-
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Dickinson), supplemented with 10% Middlebrook albumin dextrose catalase (ADC) enrichment 
(Becton-Dickinson), 10% TWEEN®-80 and 50 μg/mL of hygromycin for transposon mutant 
strains. The starter culture was incubated at 37 °C, 100 rpm for 1 week. Prior to infection of THP-
1 macrophages, a M. tb working culture was prepared. The starter culture was centrifuged at 300 
xg for 3 minutes to remove bacterial aggregates. The starter culture was then used to inoculate 5 
mL of fresh, complete 7H9 media to an OD of 1. This working culture was incubated at 37 °C, 
100 rpm overnight.  
3.8.2. THP-1 cell culture preparation and differentiation 
 Human THP-1 monocytes were obtained from the American Type Culture Collection 
(ATCC). Previously prepared frozen stocks of THP-1 monocytes stored in liquid nitrogen were 
thawed and revived in complete Roswell Park Memorial Institute (RPMI) (Gibco) supplemented 
with 10% heat inactivated fetal bovine serum (FBS) (SAFC Biosciences). The thawed monocytes 
were added to 10 mL of complete RPMI and centrifuged at 125 xg for 8 minutes to remove 
dimethyl sulfoxide (DMSO) in the freezing medium. The supernatant was discarded and the cell 
pellet was resuspended with 10 mL of fresh, complete RPMI in a vented, untreated T25 tissue 
culture flask. The THP-1 monocytes were maintained between a range of 3 × 105 cells/mL and 
8 × 105 cells/mL until there was an adequate amount of cells for the infection experiment. The 
THP-1 monocytes were differentiated with 100 ng/mL phorbol 12-myristate 13-acetate (PMA) in 
complete RPMI media and seeded in a 48-well tissue culture plate at 1 × 105  cells/well with the 
final volume of 1 mL/well. The cells were allowed to differentiate for 3 days at 37 °C, followed 
by replacement of media containing PMA with fresh RPMI media. The differentiated macrophages 
were further allowed to recover in 37 °C for 2 days prior to infection. 
3.8.3. Purified EspB preparation 
 Purified EspBWT and variants were diluted into a concentration of 1000 nM in 5 mL of 
LEW buffer. The diluted protein sample was then filtered using a 0.2 μm syringe filter. The filtered 
preparation was quantified using the BCA Protein Assay Kit similarly to Methods section 3.3.5. 
However, the filtered sample was measured without diluting. Prior to infection of THP-1 
macrophages, the EspB preparations were diluted to 80 nM in complete RPMI media. 
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3.8.4. THP-1 infection procedure  
 Differentiated THP-1 macrophages were infected similarly to a previously published study 
(Chen et al., 2013). For the groups that contained EspBWT or variants, complete RPMI media was 
prepared with 80 nM of purified and filtered EspB protein first, then working cultures of the M. tb 
5’Tn::pe35 strain was diluted to 500,000 cells/mL (multiplicity of infection (MOI) of 5) into the 
RPMI media containing EspB. For the other groups containing only bacteria, the working cultures 
of the M. tb strains were diluted to 500,000 cells/mL in fresh RPMI media prior to infection of the 
macrophages. The conditioned RPMI media in the differentiated THP-1 macrophages was 
replaced with the RPMI containing M. tb and purified, filtered EspB. THP-1 macrophages were 
infected for 3 days before measuring cytotoxicity. Prior to measuring cytotoxicity, 775 μL of media 
was removed and 25 μL of PrestoBlue HS cell viability reagent (Invitrogen) was added to each of 
the wells. The plate was incubated at 37 °C in the dark for 15 minutes to allow for conversion of 
resazurin to resorufin, and cell viability was measured using the SpectraMax i3x (Molecular 
Devices). The plate was incubated for another 15 minutes (30 minutes total) in the dark, then cell 
viability was measured.  
3.8.5. Statistical analysis of THP-1 infections 
 Statistical analysis of the cytotoxicity assays were performed on GraphPad Prism 9 
software. Percent relative cytotoxicity plots were generated using this software. Statistical 
significance differences between experimental groups were determined using one-way ANOVA. 
3.9. Localization of phospholipids with biosensors 
3.9.1. Preparation of biosensor plasmids 
 Biosensor plasmids pGFP-LactC2 and pMGFP were obtained from Sergio Grinstein 
Laboratory at the University of Toronto, (Toronto, Canada) and Guangwei Du Laboratory at the 
University of Texas (Houston, TX) respectively. The plasmids were transformed into TOP10 E. 
coli by heat shock and plated onto LB agar plates. The transformants were inoculated into LB 
media and incubated overnight at 37 °C, 200 rpm. The plasmids were purified using the EndoFree 
Plasmid Maxi Kit (Bio Basic) according to manufacturer’s instructions. Plasmids were stored in -
20 °C prior to transfection into mammalian cells. 
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3.9.2. COS-7 cell culture preparation 
 COS-7 non-human primate kidney fibroblast-like cells were obtained from ATCC. Frozen 
stocks of COS-7 cells were stored in liquid nitrogen and were thawed and revived in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma Aldrich) supplemented with 10% FBS and 0.05 
mg/mL gentamicin. The thawed cells were centrifuged in complete DMEM at 800 rpm for 8 
minutes to remove DMSO in the freezing medium. The cell pellet was resuspended in 15 mL of 
fresh, complete DMEM in a T75 treated tissue culture flask. To passage COS-7 cells, 2 mL of 
Trypsin was added to the T75 flask and incubated in 37 °C for 3-5 minutes for detachment of the 
cells. Complete DMEM was added to the cells and the cells were centrifuged at 800 rpm for 8 
minutes. The cell pellet was resuspended with fresh, complete DMEM and the appropriate split 
ratio of cell suspension was added to the T75 flask to the final volume of 15 mL. Cells were seeded 
at a density of  2.5 × 105 cells in 2 mL of DMEM in a 35 mm petri dish. The seeded cells were 
allowed to incubate overnight at 37 °C prior to transfection. 
3.9.3. Raw 264.7 cell culture preparation 
 Raw 264.7 murine macrophages were obtained from ATCC. Frozen stocks of Raw 264.7 
macrophages stored in liquid nitrogen were thawed and revived in DMEM (Sigma Aldrich) 
supplemented with 10% heat inactivated FBS, 1 mM sodium pyruvate, and 0.05 mg/mL 
gentamicin. The thawed cells were centrifuged in complete DMEM at 800 rpm for 8 minutes to 
remove DMSO in the freezing medium. The cell pellet was resuspended in 15 mL of fresh, 
complete DMEM in a T75 untreated tissue culture flask. Cells were maintained for 1 week (with 
passages every 2 days) until the number of cells were adequate for seeding. The cells were seeded 
at a density of 2.5 × 105 cells in 2 mL of DMEM in a 35 mm petri dish. The seeded cells were 
allowed to incubate overnight at 37 °C prior to transfection. 
3.9.4. Transfection of COS-7 cells and Raw 264.7 macrophages  
 The same transfection protocol was used for COS-7 and Raw 264.7 cells. Two tubes were 
set up prior to transfection: tube A with 2.0 μg of biosensor plasmid in 200 μL of Opti-MEM 
reduced serum media (Gibco) and tube B with 6 μL of Lipofectamine 2000 suspension (Invitrogen) 
in 200 μL of Opti-MEM. The contents of tube A and tube B were mixed by adding the plasmid to 
the Lipofectamine in a drop-wise fashion. This mixture was then incubated for 10 minutes in room 
temperature. During incubation of the DNA-Lipofectamine mixture, culture media was aspirated 
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from the cells and washed once with PBS and once with Opti-MEM to remove traces of serum and 
antibiotics. A volume of 400 μL of Opti-MEM was added to keep cells from drying. The DNA-
Lipofectamine mixture was added to the cells in a drop-wise fashion to a final volume of 800 μL 
in the petri dish. The cells were incubated for 4 hours at 37 °C. After incubation, the media was 
replaced with 2 mL of DMEM (without serum or antibiotics) and incubated for 24 hours prior to 



















4.1. Mapping amino acids postulated to be functionally important in EspB  
 Previously, EspB was found to have a virulence function that is distinct from other ESX-1 
substrates (Chen et al., 2013). EspB was able to induce cytotoxicity in THP-1 macrophages in the 
presence of M. tb 5’Tn::pe35 (Chen et al., 2013). In addition, it was found to bind phospholipids , 
specifically PA and PS (Chen et al., 2013). This led to the question if phospholipid binding is 
crucial for the virulence function of EspB. Furthermore, EspB was found to oligomerize into 
heptameric structures (Korotkova et al., 2015; Piton et al., 2020; Solomonson et al., 2015) . 
However, it is currently unknown whether oligomerization of EspB plays an important role in 
phospholipid binding or the virulence function of EspB. 
 A multiple alignment of the amino acid sequence of EspB from several mycobacterial 
species was performed to identify conserved residues in the protein (Figure 4.1). Several residues 
in particular were hypothesized to be functionally important for EspB in terms of phospholipid 
binding and oligomerization. The residues R17, H223, F159, and I246 were predicted to be 
involved in phospholipid binding, whereas the residues K259, K267, and W176 were predicted to 
be involved in EspB oligomerization for reasons stated below. These targeted residues were then 
mapped onto the 3D model of EspB using the UCSF Chimera molecular modelling system to 
localize the potential phospholipid binding sites and oligomerization sites. 
4.1.1. Residues hypothesized to be involved in phospholipid binding 
 The basic residues R17 and H223 were found to be highly conserved in the multiple 
sequence alignment. As anionic phospholipids such as PA and PS tend to interact with proteins 
with positive surface charges, the residues R17 and H223 were predicted to bind the negatively 
charged head groups of acidic phospholipids (Bohdanowicz and Grinstein, 2013; Chen et al., 2013; 
Stace and Ktistakis, 2006). Intriguingly, when R17 and H223 were mapped on a model of the EspB 
oligomer, the residues were located directly at the opening of either side of the EspB channel 
(Figure 4.2A). Two other residues, F159 and I246 were also predicted to be involved in 
phospholipid binding as they are located within two identified hydrophobic pockets on the EspB 
monomer (Korotkova et al., 2015). When these two residues were mapped, they were found to be 
located in close proximity to R17 and H223 (Figure 4.2B). I246 was located at the opening on one 
side of the channel, whereas F159 was located on the outer middle region of the oligomer. 
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4.1.2. Residues hypothesized to be involved in EspB oligomerization  
 The residues K259 and K267 were predicted to be involved in protein-protein interactions 
due to their close proximities in chemical cross-linking and mass spectrometry experiments 
(Solomonson et al., 2015). On the EspB oligomer model, K259 and K267 were found to be located 
in close proximity to each other within the same monomer but not from one monomer to another 
(Figure 4.3A). Next, the residue W176 is located in the WxG motif of EspB which may play a role 
Figure 4.1. Multiple alignment of EspB amino acid sequences from multiple mycobacterial 
species. Alignment was performed using MultAlin. Residues hypothesized to be involved in 
phospholipid binding are indicated with a blue arrow, whereas residues predicted to be involved 
in oligomerization are indicated with a grey arrow. 
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in stabilizing the monomeric hairpin structure, which in turn may be critical for oligomerizat ion 
of EspB (Piton et al., 2020; Solomonson et al., 2015). Mapping W176 revealed that it was located 
at the opening of the channel and was shown to interact with Y81 of the YxxxD motif on the same 




Figure 4.2. Labelled residues that are predicted to bind phospholipids targeted for 
mutation on 3D EspB model. Orientation of the oligomer was arbitrarily assigned as “Top” and 
“Bottom”. A. R17 (red) and H223 (cyan), B. F159 (green) and I246 (magenta) 
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4.2. Purification of recombinant EspB  
 Production of a large amount of protein was required in order to characterize the molecular 
basis of EspB phospholipid binding and oligomerization and to define any association between 
these features with the virulence function of EspB. Accordingly, the espB gene was cloned into a 
pET28a expression system and transformed into E. coli to produce recombinant EspB protein. The 
bacteria were harvested and lysed for purification of EspB. Ammonium sulfate precipitation was 
used as a first step of purification to precipitate proteins within the solution at different levels of 
salt saturation. SDS-PAGE was used to detect the fractions containing EspB based on its known 
Figure 4.3. Labelled residues that are predicted to be involved in oligomerization targeted 
for mutation on 3D EspB model. Residues were labelled using UCSF Chimera molecular 
modelling system. A. K259 (yellow) and K267 (purple), and B. W176 (orange) and W176 
interaction with Y81 (blue). 
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size. Next, nickel affinity chromatography was used to further purify the protein. EspB was 
constructed to contain a histidine tag at the C-terminus of the protein and therefore would be 
captured within the column while contaminating proteins were allowed to exit the column. EspB 
was then eluted using imidazole. 
 The purification protocol was first established and optimized for EspBWT, then was 
repeated with the EspB variants in the same manner. Ammonium sulfate precipitation experiments 
showed that EspB tends to precipitate out of solution at a range of 20-35% of the salt (Figure 
4.4A). This was also observed in the other EspB variants. Next, nickel-iminodiacetic acid (Ni-
IDA) affinity column revealed that EspB in elution fractions 1 and 2 were high in yield and purity 
(Figure 4.4B). The protein was mostly eluted from the column after the second elution as there 
were low levels of EspB detected in the third elution fraction. High yields of purified recombinant  
EspBWT and variants were produced using this purification method. The purified protein was then 
used for biochemical characterization to test for phospholipid binding and oligomerization. 
4.3. Characterization of recombinant EspB 
 Initially, single amino acid replacements at R17, H223, F159, I246, K259, and K267 in 
EspB were made. However, follow-up studies of these single amino acid mutants did not show 
significantly different phenotypes compared to EspBWT. Therefore, double mutations of residues 
at hypothesized phospholipid binding sites (EspBR17A/H2223A and EspBF159R/I246R) and hypothesized 
dimerization sites (EspBK259A/K267A) were constructed. In addition, a single amino acid replacement 
at the W176 residue within the WxG motif was constructed as EspBW176R. Similar sized non-polar 
Figure 4.4. Purification process of recombinant EspBWT. A. Ammonium sulfate precipitation 
of EspB. B. Ni-IDA column purification of recombinant EspB. 
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amino acid residues were chosen to replace the targeted polar residues within EspB (such as A to 
replace R17, H223, K259, and K267), and polar residues were chosen to replace the targeted 
residues (such as R to replace F159, I246, and W176). Following purification of EspBWT and 
variants, a BCA assay was performed to quantify each protein sample and equimolar amounts of 
EspBWT and variants were resolved on a denaturing gel. Each of the EspB samples were tested for 
purity of the preparations and detection by anti-EspB antibody. SDS-PAGE showed high purity of 
the EspB preparations with very small amounts of contaminating proteins (Figure 4.5A). 
Additionally, an immunoblot revealed that EspBWT and variants were all adequately detected by 
the anti-EspB antibody (Figure 4.5B). 
4.3.1. Native-PAGE analysis of recombinant EspB 
 EspB monomers (50 kDa) oligomerizes into a 350 kDa heptameric barrel structure 
(Korotkova et al., 2015; Solomonson et al., 2015). Native-PAGE has previously been used to 
analyze the oligomeric states of EspB expressed by M. tb from CF and CL, as well as purified 
recombinant EspB (Korotkova et al., 2015). EspBWT showed higher oligomeric formation in CF 
Figure 4.5. Purified EspBWT and variants resolved on SDS-PAGE. A. EspB samples resolved 
on SDS-PAGE and stained with Coomassie blue. B. EspB samples resolved on SDS-PAGE 
followed by western blot shows detection of EspBWT and variants by rat anti-EspB primary 
antibody. 
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of M. tb in comparison to CL (Korotkova et al., 2015). In addition, purified EspB showed less 
tendency to form the heptameric structures in comparison to M. tb CF (Korotkova et al., 2015). 
Native-PAGE differs from SDS-PAGE in that it resolves proteins based on size in native 
conditions rather than denaturing conditions. Using this method, oligomeric states adopted by 
native EspB can be observed. In addition to confirming purified EspBWT oligomeric states in 
native-PAGE with previous publications, the newly constructed EspB variants were also 
examined. 
 Equimolar amounts of EspBWT and variants were resolved on a native-PAGE gel to observe 
differences in oligomeric states of the samples (Figure 4.6) EspBWT showed predominantly 
dimeric, trimeric, and pentameric species. Whereas, EspBR17A/H223A adopted a hyperoligomer ized 
state. Some trimeric oligomers were observed but it was accompanied with a streaking pattern at 
the top of the gel. EspBW176R and EspBK259A/K267A formed mainly monomeric, dimeric and trimeric  
oligomers and did not show any hyperoligomerization. Lastly, EspBF159R/I246R showed an intense 
Figure 4.6. Purified recombinant EspBWT and variants resolved on native -PAGE. All EspB 
samples were added at a quantity of 10 μg and molecular weight markers in kDa are indicated on 
the left of the gel. 
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streaking pattern at the top of the gel similarly to EspBR17A/H223A. However, it is unknown if there 
are differences in the large oligomeric structures between EspBR17A/H223A. 
4.3.2. Dynamic light scattering analysis of EspB 
 The next method used for EspB oligomeric characterization was dynamic light scattering 
(DLS). In brief, the principle of DLS is based on light diffracting off of the sample particles. 
Initially, an incident laser propagates through the sample containing particles in Brownian motion 
(Mailer et al., 2015; Stetefeld et al., 2016). The random movements of the particles results in 
fluctuations of measured light intensity due to Rayleigh scattering (Stetefeld et al., 2016) (Figure 
4.7). The particle size is calculated based on the speed of the light decay (Mailer et al., 2015; 
Stetefeld et al., 2016). Smaller particles diffuse faster, corresponding to higher fluctuation of light 
intensity, whereas larger particles diffuse slower resulting in a lower fluctuation. The diffracted  
light is detected by a fast photon counter which takes measurements continuously with a preset 
interval called time delay. The data taken from each time point are compared to each other to 
obtain the correlation function (Mailer et al., 2015). The correlation of the light intensity between 
time points gives information on particle diffusion, which is related to the hydrodynamic radius of 
the particle by the Stokes-Einstein equation (refer to Appendix 1, Equation 1) (Mailer et al., 2015). 
Figure 4.7. Principle of DLS. This diagram demonstrates that larger particles diffuse at a slower 
rate, resulting in a smoother intensity plot. Whereas smaller particles tend to diffuse faster will 
have a more erratic intensity plot (Jones, 2010). 
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The radius is then used to calculate the estimated molecular weight of the sample particles. In 
addition, the polydispersity index (PDI) was calculated for each sample to determine if they were 
monodispersed or polydispersed. A value above 20% indicates that the sample is polydispersed, 
meaning that there are several oligomeric species present in the sample. DLS was therefore used 
to determine oligomerization propensities of the EspB variants in comparison to EspBWT.  
 The molecular weight estimation of approximately 226 kDa in the EspBWT sample was 
revealed to be the most abundant oligomeric species (Figure 4.8A). The PDI for EspBWT was 
estimated to be 23% which indicates that the sample was mainly monodispersed. EspBR17A/H223A 
showed an estimation of 53.9 kDa at 65% mass intensity as well as a very large oligomeric species 
of 1297 at 33.7% mass intensity (Figure 4.8B). The PDI was estimated to be 30% at the first peak 
and 67% at the second peak, indicating that there were various oligomeric species within the 
sample. EspBW176R showed an estimation of 163 kDa and did not show a tendency to form large 
oligomers (Figure 4.8C). The PDI was estimated to be 80%, showing high polydispersity. Like 
EspBW176R, EspBK259A/K267A showed a molecular weight estimation of 193.0 kDa and also did not 
form an abundance of larger oligomeric species (Figure 4.8D). However, this variant was indicated 
to be monodispersed as the PDI was estimated to be 18%. Lastly, EspBF159R/I246R showed a 
molecular weight estimation upwards of 1458.5 kDa (Figure 4.8E). This variant had a strong 












4.3.3. Transmission electron microscopy of EspB  
 To directly visualize the oligomeric states of EspBWT and its variants, transmission electron 
microscopy (TEM) was performed. This method was previously used to visualize the EspB 
oligomer where it was found that EspBWT formed heptameric barrel shaped oligomers (Korotkova 
et al., 2015; Piton et al., 2020; Solomonson et al., 2015).  
 EspBWT formed heptameric oligomers that were consistent with previous publications 
(Figure 4.9A). The heptamers were dispersed evenly and separated from one another. 
EspBR17A/H223A also showed some similar oligomeric structures but the oligomers appeared to be 
more closely associated with one another, forming larger complexes (Figure 4.9B). EspBW176R 
showed very few formations of heptameric barrels and the oligomers appeared incomplete and 
sparse (Figure 4.9C). However, EspBK259A/K267A formed very similar heptameric oligomers as 
EspBWT did (Figure 4.9D). Lastly, EspBF159R/I246R appeared to rarely form the heptameric 





Figure 4.8. DLS analysis of EspBWT and variants. Estimated molecular weight (Mw-R) of 
particles within the samples measurements are indicated in kDa. Mass distribution of each sample 
by oligomeric species are indicated in % Mass. Measurements were taken from samples containing 




 Overall, the propensity of EspBR17A/H223A and EspBF159R/I246R to hyperoligomerize were 
found to be consistent throughout native-PAGE, DLS, and TEM analyses. Whereas, EspBW176R 
and EspBK259A/K267A showed similar oligomeric formations as EspBWT. However, the data obtained 
from native-PAGE and DLS analyses did not reveal how the oligomeric structures of each variant 
were formed. Therefore, TEM was used to directly visualize these oligomeric structures. Although 
the variants EspBR17A/H223A and EspBF159R/I246R both had the tendency to hyperoligomerize, their 
structures were vastly different. In addition, native-PAGE and DLS analyses revealed similar 
Figure 4.9. TEM imaging of EspBWT and variants. All images were taken at 100K 
magnification. All protein samples A. EspBWT, B. EspBR17A/H223A, C. EspBW176R, D. 
EspBK259A/K267A, and E. EspBF159R/I246R were prepared at 150 μg/mL concentration. 
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molecular weights of the oligomers formed in EspBW176R and EspBK259A/K267A to EspBWT. 
However, TEM analysis reveal some differences of the EspBW176R oligomeric structure from 
EspBWT. 
4.4. Characterization of EspB phospholipid binding 
 Pure EspB was previously found to bind phospholipids, specifically PA and PS in vitro 
(Chen et al., 2013). These phospholipids are involved in important macrophage processes such as 
phagosome maturation (Bohdanowicz and Grinstein, 2013). This led to the hypothesis that 
phospholipid binding may be critical for the virulence function of EspB. In addition, the EspB 
monomer was found to contain hydrophobic pockets predicted to bind the fatty acid region of 
phospholipids (Korotkova et al., 2015). The conserved basic residues R17 and H223 that were 
identified in a sequence alignment were also are predicted to be involved in binding the negatively 
charged head groups of acidic phospholipids. The EspB variants constructed in this project was 
tested for their phospholipid binding abilities.  
4.4.1. Phospholipid membrane overlay assay 
 Phospholipid spotted membranes were used to assess EspBWT binding to specific 
phospholipids in comparison with the previous EspB study (Chen et al., 2013). In addition, 
phospholipid interactions of the newly constructed EspB variants were observed. Two types of 
phospholipid spotted membranes were used in this project: commercially made membranes were 
purchased from Echelon Biosciences and custom phospholipid arrays were made in the laboratory.  
 The commercially made phospholipid spotted membranes were used to assess the 
specificity of the phospholipid binding by EspB (Figure 4.10). EspBWT was observed to bind to 
PA similarly to the previous study (Chen et al., 2013). However, it was also detected to bind 
PI(3,5)P2, PI(3)P, PI(4)P, and PI(5)P. EspBR17A/H223A showed a lack of PA binding as well as 
PI(3,5)P2, PI(3)P, PI(4)P, and PI(5)P. EspBW176R showed similar phospholipid binding intensity as 
EspBWT to PA as well as the phosphoinositides. Interestingly, EspBK259A/K267A showed a slight 
reduction in binding these phospholipids. In contrast, EspBF159R/I246R was able to bind PA in the 
same manner as EspBWT but showed increased binding to PI(3,5)P2, PI(3)P, PI(4)P, and PI(5)P. 
 Custom laboratory-made phospholipid membrane arrays were used to determine if there 
were differences of the EspB variants in terms of their affinity to PA binding (Figure 4.11). These 
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membranes were used as a more economical alternative in comparison to the costly commercially 
produced membranes. Each membrane was spotted with decreasing amounts of PA and PS starting 
at 400 pmol and diluted 2 fold. The spotted membranes were incubated with EspBWT, 
EspBR17A/H223A, EspBW176R, EspBK259A/K267A, or EspBF159R/I246R, followed by immunoblott ing. 
EspBWT showed strong binding to PA, whereas EspBR17A/H223A showed a very weak affinity to PA. 
EspBW176R showed a similar binding intensity to PA as EspBWT. Consistently, EspBK259A/K267A 
showed a slight reduction in PA affinity. Lastly, EspBF159R/I246R showed similar affinity to PA as 
EspBWT. 
4.4.2. Phospholipid bead pull-down assay 
 The second method used to test EspB-phospholipid interactions was the use of 
phospholipid coated agarose beads. These commercially produced beads were coated with a 
phospholipid of choice and incubated with the target protein to test phospholipid binding. PA and 
PS coated beads were used for each of these variants and control beads (without phospholipid 
coating) was used as a negative control. This experiment was repeated twice per variant comparing 
to EspBWT (Figure 4.12). EspBWT showed strong binding to PA beads, whereas EspBR17A/H223A was 
unable to bind PA. EspBW176R showed similar binding to PA as EspBWT and EspBK259A/K267A 
showed reduced binding. Lastly, EspBF159R/I246R showed similar PA binding as EspBWT. 
Figure 4.10. Commercially produced phospholipid membrane overlay assay of EspB WT and 
variants. Phospholipids used for this assay are indicated on the first membrane. Each membrane 
was incubated with either EspBWT, EspBR17A/H223A, EspBW176R, EspBK259A/K267A or EspBF159R/I246R. 
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 These phospholipid binding assays revealed that EspBWT was able to bind PI(3,5)P2, 
PI(3)P, PI(4)P, and PI(5)P in addition to the previously reported PA. The EspB mutants showed 
variable levels of phospholipid binding: EspBR17A/H223A lacked binding in all of the tested 
phospholipids, EspBW176R showed similar phospholipid binding levels as EspBWT, EspBK259A/K267A 
showed slightly reduced phospholipid binding, and interestingly, EspBF159R/I246R showed enhanced 
binding to  PI(3,5)P2, PI(3)P, PI(4)P, and PI(5)P. However, EspBF159R/I246R bound to PA at similar 
levels to EspBWT as confirmed in the custom laboratory-made phospholipid spotted membranes 
and the phospholipid bead pull-down assay. 
4.5. Enhancement of M. tb 5’Tn::pe35 induction of cytotoxicity in macrophages  
 Previously, it was shown that EspBWT was able to enhance M. tb 5’Tn::pe35 induction of 
cytotoxicity in THP-1 macrophages (Chen et al., 2013). The transposon strain M. tb 5’Tn::pe35  
was unable to secrete EspB and did not induce high levels of cytotoxicity in macrophages (Chen 
et al., 2013). However, exogenous addition of purified recombinant EspB was able to restore its 
virulence to the same level as M. tb espA::Tn (Chen et al., 2013). It was hypothesized that the 
virulence function of EspB was due to its ability to bind phospholipids which caused the induction 
of cytotoxicity in THP-1 macrophages. Therefore, the next step was to observe if the inability of 
Figure 4.11. Phospholipid binding of EspB WT and variants using custom laboratory-made 
lipid spotted membranes. Membranes were allowed to incubate with A. EspBWT and 




EspBR17A/H223A to bind phospholipids has consequences to M. tb virulence during infections. In 
order to test this, purified EspB variants were added to M. tb 5’Tn::pe35 prior to infecting THP-1 
macrophages. 
 Prior to infection, THP-1 monocytes must first be differentiated into macrophage-like cells 
using an optimal concentration of PMA. Differentiation of THP-1 monocytes to macrophages has 
been previously described in many studies and is a recognized protocol. These differentiated 
macrophages are very similar to human peripheral blood mononuclear cell monocyte-derived 
macrophages and are adherent with lower proliferation rates (Starr et al., 2018). The THP-1 cells 
must be differentiated into macrophage-like cells in order to ensure that the infection experiment 
was performed on a biologically relevant cell type. However, since the differentiation process is a 
harsh treatment to the cells, the concentration of PMA must be adjusted to ensure optimal 
differentiation but healthy cells prior to infection with M. tb. The PMA concentration used for 
these experiments were 100 ng/mL for 3 days followed by 2 days of recovery in fresh RPMI media. 
Figure 4.12. Phospholipid coated bead pull-down assay using EspBWT and variants. Expected 
EspB molecular weight is indicated on the left of each western blot. Each EspBWT or variant were 
incubated separately with either PA, PS or control beads and are indicated on the top of each 
western blot membrane. 
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THP-1 monocytes 24 hours post treatment with PMA were not fully differentiated and displayed 
a round morphology with a defined membrane (Figure 4.13A). However, after treatment with 
PMA, the macrophage-like cells showed large and irregularly shaped cells with the membrane 
much less defined than undifferentiated cells (Figure 4.13B). These cells were also adherent and 
had very slow proliferation. 
 After PMA treatment of the THP-1 cells, the media was replaced with fresh RPMI media 
for cells to recover for 48 hours prior to infection with M. tb. The THP-1 cells were infected with 
WT M. tb or M. tb transposon mutant at an MOI of 5. After infection for 72 hours, cell viability 
was measured using PrestoBlue viability reagent. This reagent is resazurin based where viable 
cells will convert resazurin to fluorescent resorufin to allow for direct measurement of cell viability 
as relative fluorescence units (RFU). The RFU values for each treatment group was compared to 
RFU values of uninfected THP-1 macrophages to calculate the % relative cytotoxicity using 
Equation 2 (refer to Appendix 1). The results were plotted as % relative cytotoxicity on Graphpad 
Prism 9 and statistical analysis was performed using one-way ANOVA with Tukey post-hoc test 
to determine significant differences between groups. There were no significant difference between 
EspBWT and EspBR17A/H223A’s ability to enhance the virulence of 5’Tn::pe35 (Figure 4.14) . This 
suggests that the virulence function of EspB may be more complex than previously hypothesized 
and that phospholipid binding may not be the only aspect to its virulence. 
Figure 4.13. Differentiation of THP-1 cells using PMA treatment. A. Cells were imaged at 24 
hours post-PMA treatment and B. at 72 hours post-PMA treatment.   
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 The lack of difference in induction of cytotoxicity between EspBWT and EspBR17A/H223A 
raised a question of whether the addition of EspB without the presence of bacteria would be able 
to induce cytotoxicity in the THP-1 macrophage. To address this, EspBWT or EspBR17A/H223A was 
added to THP-1 macrophages without the presence of M. tb. The infection was performed in the 
same manner as the previous cytotoxicity experiment. Addition of either EspBWT or EspBR17A/H223A 
alone to THP-1 macrophages demonstrated that EspB alone was unable to induce cytotoxicity in 
macrophages as EspB with M. tb 5’Tn::pe35 did (Figure 4.15). The data was plotted using RFUs 
to better convey that there were no differences in cell viability between these groups and non-
treated macrophages. 
Figure 4.14. Cytotoxicity enhancement of M. tb 5’Tn::pe35 by EspBR17A/H223A to infect THP-
1 macrophages. The data in this figure represents an average of 3 independent experiments. One-
way ANOVA was used to analyze differences between all the treatment groups F4,10 = 60.47, p < 
0.001) and a Tukey post-hoc test was performed to compare differences between two of the 
treatment groups (α 0.05). There was no significant difference between M. tb 5’Tn::pe35 + EspBWT 
and M. tb 5’Tn::pe35 + EspBR17A/H223A (p > 0.999) denoted with “ns”. Whereas, there was a 
significant difference between M. tb 5’Tn::pe35 + EspBWT and M. tb 5’Tn::pe35 alone (p < 0.001) 
denoted by an asterisk *.  
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 A cytotoxicity assay was also performed to compare the effects of EspBW176R, 
EspBK259A/K267A, or EspBF159R/I246R added to M. tb 5’Tn::pe35 in comparison to EspBWT (Figure 
4.16). However, this experiment was performed only once and therefore statistical analysis was 
not performed. From the results, addition of EspBW176R, EspBK259A/K267A, and EspBF159R/I246R does 
not appear to have a significant effect on cytotoxicity enhancement of M. tb 5’Tn::pe35 in 
comparison to EspBWT. However, it seems that EspBW176R and EspBK259A/K267A induced slightly 
lower levels of cytotoxicity and their effects may not be fully captured by this assay. 
 These infection assays revealed no significant differences between EspBWT and 
EspBR17/H223A to induce cytotoxicity to THP-1 macrophages when added to M. tb 5’Tn::pe35.  
There were also no differences found between EspBW176R, EspBK259A/K267A, and EspBF159R/I246R in 
comparison to EspBWT. Furthermore, addition of purified EspBR17A/H223A or EspBWT to THP-1 
macrophages alone was unable to induce cytotoxicity. 
Figure 4.15. Effect of EspBWT or EspBR17A/H223A addition to THP-1 macrophages alone. Cell 
viability was measured in RFU. THP-1 macrophages either received no treatment (NT), infected 
with WT M. tb, or received addition of either EspBWT or EspBR17A/H223A alone. 
51 
4.6. Preparation of PA and PS reporter macrophages  
 EspB was previously shown to bind mammalian phospholipids in vitro, this interaction was 
hypothesized to be important for the virulence function of EspB (Chen et al., 2013). During M. tb 
infection of macrophages, it is possible that EspB-phospholipid interactions can disrupt the 
signaling roles of these important phospholipids. Therefore, reporter macrophages can be used to 
directly observe EspB-phospholipid interactions at a cellular level. Plasmids used as PA and PS 
biosensors were obtained from the Guangwei Du Laboratory at the University of Texas (Houston, 
TX) and the Sergio Grinstein Laboratory at the University of Toronto (Toronto, Canada) 
respectively. These plasmids encode a probe that specifically binds PA or PS tagged with GFP for 
Figure 4.16. Cytotoxicity enhancement of M. tb 5’Tn::pe35 by EspBW176R, EspBK259A/K267A, 
and EspBF159R/I246R in comparison to EspBWT. Relative cytotoxicity of differentiated THP-1 
macrophages infected with WT M. tb, espA::Tn, 5’Tn::pe35 or 5’Tn::pe35 with 80 nmol of 
EspBWT, EspBW176R, EspBK259A/K267A or EspBF159R/I246R. 
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visualization on confocal microscopy. The plasmid specific for PA (pMGFP-PASS) was an 
improved biosensor from its previous counterpart, GFP-Spo20-PABD, which was constructed 
from the PA binding domain of a Saccharomyces cerevisiae protein, Spo20 (Zhang et al., 2014). 
However, sensitivity in pGFP-PASS was improved by the addition of a nuclear export sequence 
(NES) from protein kinase A inhibitor α (PKI-α) (Zhang et al., 2014). Next, the  plasmid specific 
for PS (pLact-C2) specific for PS was constructed from the C2 domain of lactadherin with the 
inclusion of a GFP tag (Yeung et al., 2008). The cell line initially used for this assay were COS-7 
non-human primate kidney fibroblast-like cells in order to optimize the transfection procedure. 
These cells were transfected with pGFP-PASS or pLact-C2 plasmids and were imaged using 
confocal microscopy (Figure 4.17). GFP signal was present in both transfected groups which 
indicated that the transfection was successful and the plasmids were functional. Localization of 
PA was shown to be ubiquitous throughout the cell (Figure 4.17A). COS-7 cells transfected with 
pLact-C2 displayed a more specific localization of the GFP signal (Figure 4.17B). 
 While this experiment demonstrated that the transfection protocol was successful, COS-7 
cells are not a biologically relevant cell line used to study M. tb infections. Therefore, the next 
objective was to transfect Raw 264.7 murine macrophages. Raw macrophages transfected with 
pMGFP-PASS also showed a ubiquitous GFP signal similarly to the COS-7 transfected cells  
(Figure 4.18A). However, the macrophages transfected with pLact-C2 showed similar specific 
localization of the GFP signal as COS-7 cells transfected with this plasmid (Figure 4.18B). 
 Ultimately, these reporter macrophages were generated in attempts to further the study of 
EspB-phospholipid interactions within the cell during M. tb infection. Future studies of this 
interaction would include construction of M. tb strains expressing EspBWT or other EspB variants 
and used to infect these reporter macrophages to monitor any differences in the intensity of GFP 




Figure 4.17. Transfection of COS-7 cells. Cells were transfected with A. pMGFP-PASS plasmid 
and B. pLact-C2 plasmid. Image was processed on Leica Application Suite (LasX). Scale bars are 
25 μm. 
 
Figure 4.18. Transfection of Raw 264.7 murine macrophages. Cells were transfected with A. 





5.1. Mapping residues presumed to be functionally important for EspB  
 Prior to characterization of the EspB variants, the residues that were hypothesized to be 
functionally important for EspB were targeted for mutagenesis. These residues were mapped on 
the 3D model of the EspB oligomer using the modelling software, Chimera. Through this exercise, 
the basic residues thought to be crucial for phospholipid binding, R17 and H223A were found to 
be localized at the immediate opening of the EspB channel. Furthermore, multiple sequence 
alignment of EspB from multiple mycobacterial species identified that these two residues were 
highly conserved. The localization of R17 and H223 at both sides of the EspB channel opening 
was significant as this may allow for easy access for phospholipid interaction by EspB. In addition, 
these residues are basic which would have the capacity to bind the negatively charged head groups 
of acidic phospholipids such as PA and other phosphoinosit ides. This is consistent with the 
specificity of the phospholipid interaction by EspB that was previously reported (Chen et al., 
2013). Two other residues predicted to bind the fatty acid region of EspB, F159 and I246, are 
localized at the interior of the EspB oligomeric channel (Korotkova et al., 2015). It was previously 
shown that the overall charge of the EspB interior channel is positive which is consistent with the 
placement of these two residues. It is possible that R17 and H223 are responsible for binding 
negatively charged head groups of acidic phospholipids, while F159 and I246 binds the fatty acid 
regions of the phospholipids. 
 Residues that were predicted to be involved the oligomerization of EspB, K259 and K267, 
were found to be localized to the interior of the EspB channel (Solomonson et al., 2015). Although 
these residues were hypothesized to be involved in oligomerization of EspB, they may not be 
involved in oligomerization. Through chemical cross-linking coupled mass spectrometry using 
cyanur-biotin-dimercapto-propionyl-succinimide (CBDPS), it was found that K259 and K267 
residues were located within 25 Å with one another (Solomonson et al., 2015). However, it was 
found that the intermolecular contacts (crystal contacts) within the crystallized protein differs from 
the ones mediating EspB oligomerization. Therefore, it is possible that these residues are not 
involved in EspB oligomerization which was reflected in the native-PAGE, DLS, and TEM results.  
The residue W176 that is involved in stabilization of the EspB monomer hairpin was found to be 
located at one end of the EspB channel, and was demonstrated to interact with Y81 within the 
same monomer (Piton et al., 2020; Solomonson et al., 2015). It was hypothesized that if the 
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interaction between W176 and Y81 was abolished, it may affect the formation of the monomer 
hairpin structure and as a result, may compromise the oligomeric structure of EspB. These results 
thus motivated the construction and characterization of EspB with mutations in these residues 
predicted to be important for EspB. 
5.2. Purification and antibody detection of EspB WT and variants 
 EspB variants were purified prior to performing any biochemical assays for 
characterization. Previously, single amino acid replacements of R17, H223, F159, I246, K259, and 
K267 were made in EspB. However, due to the mild phenotypes revealed from follow -up 
biochemical characterization assays, double mutations in EspB were constructed for further 
assessment. During purification, two of the four variants, EspBR17A/H223A and EspBF159R/I246R 
consistently had lower purification yields compared to EspBWT, EspBW176R, and EspBK259A/K267A.   
This is intriguing as EspBR17A/H223A and EspBF159R/I246R showed a tendency to hyperoligomer ize 
under native-PAGE conditions as well as in DLS and TEM results. Therefore, the quantification 
step following purification of the variants was crucial to ensure that equivalent amounts of protein 
variants were used in each assay. In addition, all of the EspB variants were detected by the α-EspB 
primary antibody equivalently and therefore, the results obtained in the following experiments 
were due to the phenotypes of the EspB variants themselves and not due to differential detection 
by the anti-EspB antibody. 
5.3. Oligomerization of EspB 
 Native-PAGE was first used to observe oligomerization of EspBWT and variants. The 
variants, EspBR17A/H223A and EspBF159R/I246R both showed the tendency to hyperoligomerize under 
native-PAGE conditions. It was observed during the purification process of EspBR17A/H223A and 
EspBF159R/I246R resulted in a lower yield compared to other EspB variants. This could have resulted 
from inefficient elution from the Ni-IDA purification columns due to their hyperoligomeric 
properties. The two variants EspBW176R and EspBK259A/K267A were observed to form similar 
oligomeric patterns as EspBWT. Although these variants were constructed in order to eliminate  
oligomerization of EspB, this experiment demonstrated that the residues K259 and K267 were 
most likely not involved in oligomerization of EspB. However, it is possible that replacement of 
the residue W176 did not fully abrogate the interaction between the WxG and the YxxxD motif on 
the EspB monomer and therefore did not affect the oligomerization of this variant.  
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 In order to verify the results observed in the native-PAGE assay, DLS was used as another 
method to characterize EspB oligomerization. The results obtained using DLS showed similar 
trends to the native-PAGE results. Both EspBR17A/H223A and EspBF159R/I246R showed 
hyperoligomerization, whereas EspBW176R and EspBK259A/K267A showed similar oligomeric species 
as EspBWT. In addition, all variants showed a PDI of above 20%, suggesting that there were 
multiple oligomeric species present in all samples. However, the molecular weight values 
estimated through DLS did not correspond to previously published values of the molecular size of 
EspB. The inconsistencies in molecular weight estimation here compared to previously reported 
values may be due to the method in which DLS uses to approximate particle size. Since DLS 
estimates particle size based on hypothetical perfect spheres that would scatter light the same way 
the sample particles would, this could lead to overestimation or underestimation of the molecular 
weight (Figure 5.1). 
 Both native-PAGE and DLS demonstrated that EspBR17A/H223A and EspBF159R/I246R had a 
tendency to hyperoligomerize, whereas EspBW176R and EspBK259A/K267A showed similar oligomeric 
patterns as EspBWT. However, these assays did not confirm if the oligomers that the EspB variants 
formed were the same as EspBWT. Therefore, TEM was used to directly visualize the oligomers 
that EspB variants were forming. EspBR17A/H223A was observed to form heptameric barrel structures 
similar to that of EspBWT. However, the heptamers were clustered together to form a larger, more 
complex oligomer that was likely reflected in the results of the native-PAGE and DLS assays. In 
contrast, EspBF159R/I246R formed large complexes that did not resemble heptameric barrels observed 
Figure 5.1. DLS estimation of sample particle size based on hydrodynamic radii.  Particle 
size is estimated by the dotted blue circle denoted with the hydrodynamic radius (Rh) which can 
result in either over- or under-estimation (Kundu, 2019). 
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in EspBWT. EspBW176R was observed to form very sparse heptameric oligomers that were similar 
to EspBWT. It is possible that altering W176 that is involved in stabilization of the EspB hairpin 
may have slightly compromised the oligomerization. Lastly, EspBK259A/K267A showed similar 
heptameric structures as EspBWT. This variant was not compromised in its oligomeric formation 
in native-PAGE, DLS, or TEM analyses. Therefore, it could be possible that these residues were 
not involved in oligomeric formation of EspB. 
5.4. Phospholipid interactions of EspB 
 As EspBWT was previously found to bind specifically to PA, the variants that were 
constructed in this project were examined for their phospholipid binding abilities using a 
phospholipid membrane overlay assay (Chen et al., 2013). Two types of membranes were used for 
this experiment: commercially produced phospholipid spotted membranes to observe specificity 
of the phospholipid binding and custom made phospholipid spotted arrays to observe the affinity 
of EspB-PA binding.  
 Interestingly, EspBWT was observed to bind to PI(3,5)P2, PI(3)P, PI(4)P, and PI(5)P in 
addition to binding PA. However, EspBR17A/H223A lacked binding to all of these phospholipids. It 
appeared that the residues R17 and H223 played a significant role in EspB phospholipid binding, 
and mutation of these residues to uncharged residues resulted in its inability to bind phospholipids. 
On the contrary, EspBF159R/I246R was observed to bind PA similarly to EspBWT, but also had 
enhanced binding to the phosphoinositides. It is possible that the change from F159 and I246 to a 
basic residue is contributing to increased binding to the acidic phospholipids. Although both the 
EspBR17A/H223A and EspBF159R/I246R variants showed hyperoligomerization, these variants differed 
in their oligomeric patterns as well as their abilities to bind phospholipids. It suggested that the 
oligomeric structure that EspB forms does not dictate its ability to bind phospholipids. EspBW176R 
had similar binding to phospholipids as EspBWT, suggesting that the residue W176 may not be 
involved in phospholipid binding. Interestingly, EspBK259A/K267A showed a reduction in 
phospholipid binding in comparison to EspBWT. It is possible that a mutation at the residues K259 
and K267 introduced a structural hindrance to the residues that were involved in phospholipid 
binding.  
58 
 The results obtained from the phospholipid membrane overlay assay were verified using 
another method, phospholipid bead pull-down assay. Agarose beads that were coated with specific 
phospholipids were used to detect EspB binding. Using this method, similar findings were 
obtained. EspBR17A/H223A was unable to bind PA, whereas EspBF159R/I246R and EspBW176R showed 
similar PA binding intensity as EspBWT. EspBK259A/K267A also showed reduced PA binding using 
this method. EspB non-specifically binding to control beads were observed in performing this 
assay. However, the pattern of EspB-PA binding was consistent within repetitions of this assay as 
well as consistent with the membrane overlay assay. For further studies, it is possible to use a non-
interacting phospholipid coated bead as negative control rather than control beads. 
5.5. THP-1 infection 
 It was previously shown that addition of purified EspBWT to M. tb 5’Tn::pe35 enhanced its 
virulence to the same level as that of the M. tb espA::Tn mutant (Chen et al., 2013). Following 
biochemical characterization of EspBWT and variants constructed in this project, a cytotoxicity 
assay was performed to observe if EspB variants would be able to enhance the virulence of M. tb 
5’Tn::pe35. It was previously demonstrated that EspBR17A/H223A was unable to bind phospholipids. 
Therefore, this variant was used to determine if lack of phospholipid binding would affect its 
virulence function. Like EspBWT, addition of EspBR17A/H223A was able to enhance the cytotoxic 
potential of M. tb 5’Tn::pe35 towards THP-1 macrophages. Likewise EspBF159R/I246R, EspBW176R, 
and EspBK259A/K267A also enhanced M. tb 5’Tn::pe35 cytotoxicity towards THP-1 macrophages.  
 These results suggests that the virulence function of EspB may be more complex than 
previously appreciated and may not solely depend on phospholipid binding. Addition of EspBWT 
or EspBR17A/H223 alone to THP-1 macrophages did not induce cytotoxicity. This suggests that EspB 
requires the presence of M. tb in order to have a virulence function. Furthermore, none of the 
variants in this project were truly abolished in its ability to oligomerize. It was demonstrated from 
a pre-print study from bioRxiv by Gijsbers et al., that EspB from pathogenic mycobacteria are able 
to oligomerize whereas EspB from non-pathogenic species such as M. smegmatis did not show 
oligomerization (Gijsbers et al., 2021). Therefore, future testing on an EspB variant completely 
abolished in oligomerization may be necessary to determine if it is crucial to EspB’s virulence 
function. Although phospholipid binding may not strictly correlate with the virulence function of 
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EspB, this function may be due to another factor such as mitochondrial damage of the infected 
host cell. 
 M. tb was previously found to induce mitochondrial damage and fragmentation in the 
infected host cell, and leading to necrotic cell death (Spier et al., 2019; Wiens and Ernst, 2016a, 
2016b). Infection with M. tb causes mitochondrial stress which contributes to IFN-β induction as 
well as mitochondrial membrane disruption, leading to mitochondrial outer membrane 
permeabilization (MOMP) and cytochrome c release (Spier et al., 2019; Wiens and Ernst, 2016a). 
The increase in mitochondrial membrane permeability leads to damage and fragmentation of the 
mitochondria, resulting in induction of necrotic cell death (Spier et al., 2019; Wiens and Ernst, 
2016a). Although it is currently unclear how this is caused, it is possible that EspB contributes to 
mitochondrial damage. It was reported that M. africanum induces less mitochondrial stress and 
less IFN-β than the virulent M. tb (Wiens and Ernst, 2016a, 2016b). The inability of M. africanum 
to induce mitochondrial damage could be due to it containing a premature stop codon at the espK 
gene, leading to lack of secretion of EspB (Wiens and Ernst, 2016a). Current work at the Chen 
Laboratory has also revealed that an M. tb strain lacking in EspK expression is unable to secrete 
EspB and furthermore, induces less mitochondrial damage compared to WT M. tb (unpublished 
data). In addition, as it is known that PA has a crucial role in regulating mitochondrial fission and 
fusion, EspB interaction with PA may interfere with this function (Chen et al., 2013; Yang and 
Frohman, 2012). This mechanism of the mitochondria is important especially during cellular 
metabolic or environmental stress (Youle and Van Der Bliek, 2012).  
5.6. Preparation of PA and PS reporter macrophages  
 As EspB was found to interact with mammalian phospholipids within the cell, reporter 
macrophages specific for sensing PA and PS was constructed in this project. Plasmids encoding 
probes that specifically interact with PA or PS and tagged with GFP were used for transfecting 
mammalian cells. This would be a promising tool for further studying the interaction of EspB and 
specific phospholipids within an intracellular environment. Two cell lines were used: COS-7 
kidney fibroblast-like cells and Raw 264.7 murine macrophages. GFP signal was detected in both 
transfected COS-7 cells and Raw 264.7 cells. Although the transfection was successful, GFP signal 
observed in pGFP-PASS transfected reporter macrophages was ubiquitous and did not show 
specific localization. As this assay is in its early stages of development, the transfection procedure  
60 
should be optimized with some considerations: ratio of transfection reagents and the transfection 
duration. During the transfection procedure, the ratio of plasmids and Lipofectamine 2000 used 
should be optimized in order for the transfected cells to express an optimal level of the biosensing 
probe. Determining the best time point to image the cells in order to capture a more specific 
localization of the biosensor within the cells.  
 The goal of generating reporter macrophages was to observe any difference between 
phospholipid levels or localizations during infection with M. tb. Therefore, the logistics of the 
transfection procedure in conjunction with M. tb infection should be considered. Since M. tb is a 
biosafety level 3 pathogen, the reporter macrophages must be transported into containment in order 
to perform the infection. Taken together with the optimal time point for imaging post-transfected 
cells, this could pose some difficulty in the experiment. Furthermore, the transfection procedure 
itself is a harsh treatment to the cells. Therefore, necessary controls must be included to account 













6. Conclusions and Future Directions 
 The aim of this project was to further characterize the virulence function of EspB in its 
secreted form. Several mutations were made at residues predicted to be functionally important for 
EspB. These constructed variants were used for characterizing oligomerization and phospholipid 
binding of EspB. Two variants in particular, EspBR17A/H223A and EspBF159R/I246R were found to 
hyperoligomerize in native-PAGE, DLS, and TEM analyses. Whereas, EspBW176R and 
EspBK259A/K267A showed similar heptameric formation as EspBWT. Altering the residue W176 
appeared to have little effect on oligomerization of EspB. It is possible that a variant containing 
mutations in both W176 and its interacting residue Y81 may show a more significant difference in 
its oligomerization properties. In addition, it was reported by Gijsbers et al. that double mutation 
of the residues N55 (at the core of monomer) and T119 (at the PE-PPE linker) to C abolished 
oligomerization of EspB (Gijsbers et al., 2021). This mutation was found to prevent the linker 
from adopting a different conformation needed for oligomerization (Gijsbers et al., 2021). 
Therefore, this variant would be a good candidate to determine if the ability of EspB dimerization 
is crucial for its interaction with phospholipids. 
 Although the two variants EspBR17A/H223A and EspBF159R/I246R both displayed 
hyperoligomerization, they revealed opposite phenotypes in terms of phospholipid binding. 
Therefore, it is possible how EspB forms its oligomers does not necessarily affect phospholipid 
binding. Interestingly, EspBK259A/K267A showed reduced phospholipid binding. It is possible that a 
change from a basic residue (such as lysine) to a non-polar residue (alanine) affected the ability of 
this variant to bind phospholipids. An assay testing phospholipid binding strength could potentially 
give more information on the reason why this variant displayed this phenotype.  
 A more recent study on EspB shows evidence that EspB may be a structural component to 
the ESX-1 secretion system (Gijsbers et al., 2021). It is possible that in addition to forming a 
heptameric structure, the oligomers themselves may organize into a tubular structure summarized 
in Figure 6.1. However, mutation of certain residues may result in irregular complex formations 
that may hinder EspB function. Further studies are needed to determine if these EspB variants 
function differently from EspBWT. 
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 Future experiments to further this project would be to construct an M. tb strain with an 
espB knockout. A plasmid encoding espB variants constructed in this project can be used to 
complement the espB M. tb knockout strain. These constructed strains would be used to study 
secretion of the EspB variants, induction of cytotoxicity in macrophages, as well as cytokine 
analysis. In addition, they would be used to infect reporter macrophages generated in this project 
to observe for differences in levels and localization of GFP signals. Since an EspB variant that is 
unable to oligomerize was demonstrated by Gijsbers et al. in a pre-print article in bioRxiv, this 
variant can be constructed to further define if monomeric EspB is able to bind phospholipids and 




Figure 6.1. Summary of EspBWT and variants oligomerization and phospholipid binding  
patterns. This schematic summarizes the different oligomeric formations and phospholipid 
binding ability of each EspB variant found in this project. Each cylinder structure represents one 
EspB heptamer. Dashed lines indicates that the variant may not be readily forming heptameric 
oligomers similarly to EspBWT. However, the exact conformations that these variants are adopting 
have yet to be confirmed. 
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Equation 1: Radius of particles within sample calculated by DLS instrument where R is the 
radius of the particles, kB is the Boltzmann constant, T is the temperature, ƞ is the viscosity of the 





 × 100% = % 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 
Equation 2: RFU values obtained from treatment groups were compared to RFU values from 
uninfected THP-1 macrophages to calculate the percent relative cytotoxicity. 
 
 
